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1. INTRODUCTION 
 
Urinary tract infections (UTIs) are among the most common bacterial infections 
worldwide, as about 50% of women will experience at least one episode of UTI during their 
lifetime [1]. UTIs are also one of the leading causes of antibiotic consumption [2] and they 
represent about 40% of hospital acquired infections [3] with substantial financial implications 
and significant consequences to morbidity and mortality. 
In the era of rapidly increasing antibiotic resistance the better understanding of the 
pathogenesis of UTIs and the role of virulence factors in the different clinical manifestations of 
urinary tract infections is of utmost importance. Despite the extensive research and major efforts 
that have been made in the field, there are still many questions regarding the molecular 
background of disease diversity and the interactions between bacteria and host.  
 
1.1. Urinary tract infections 
 
In healthy individuals the bladder and the upper urinary tract are sterile. Pathogens 
predominantly reach the urinary tract by ascending through the urethra, the other possible route 
is by haematogenous or lymphatic spread, usually to the kidneys. In women UTIs can be 
classified as lower urinary tract infections when the infection is restricted to the urethra 
(urethritis) or bladder (cystitis) and upper UTIs, when the kidneys are affected (pyelonpehritis). 
In case of an uncomplicated UTI there are no anatomical or functional complicating factors. In 
male patients or if one or more of these factors are present UTIs are considered as complicated. 
 
1.1.1. Uropathogens 
 
In most of the cases UTIs are caused by Gram-negative bacteria from the intestinal flora. 
The most important pathogen is Escherichia coli, being responsible for 70-95% of 
uncomplicated lower UTIs. Proteus mirabilis and Klebsiella pneumonie may be causative 
pathogens as well (2-5%). Pseudomonas aeruginosa is also an important Gram-negative 
bacterium, which can be found mostly in case of hospital acquired infections. The role of Gram- 
positive pathogens, such as Enterococcus faecalis shows an increasing trend due to the modern 
endourological practice and increased use of urinary foreign bodies. Rare pathogens such as 
Corynebacterium urealyticum or Mycobacterium tuberculosis can also be involved in UTIs. 
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1.1.2. Bacterial virulence factors 
 
Virulence factors refer to the properties that enable a microorganism to establish itself 
and replicate on or within a specific host species, and that enhance the microbe’s potential to 
cause disease [4]. Crucial virulence factors of uropathogenic E. coli (UPEC) confer resistance 
to the effects of the host defense and in addition, virulent bacteria are able to produce molecules 
that actively inhibit the immune response of the host, thereby enhancing bacterial persistence 
and tissue damage. The genes encoding virulence factors of UPEC are localized to 
chromosomal gene clusters called “pathogenicity islands” [5, 6]. The different virulence factors 
act in concert, their expression may be turned on or off during the course of the infection and 
can be regulated by environmental signals [7]. Many different factors have been implicated in 
UPEC pathogenesis, however, the specific factors that differentiate UPEC strains responsible 
for the different clinical manifestations of UTIs remain unclear. 
Bacterial adherence to mucosal surfaces is considered to be a critical virulence factor. 
Fecal isolates, strains causing asymptomatic bacteriuria (ABU), cystitis or pyelonephritis differ 
in their adherence capacity to uroepithelial and vaginal cells [8]. The uropathogenic clones are 
usually fimbriated and may express several adhesive surface organelles, such as P, type 1 and 
S fimbriae [9, 10] [11, 12]. Adherence factors other than the P and type 1 fimbriae are less well 
studied, and their potential role as virulence determinants has not yet been convincingly shown. 
The most important virulence factors will be discussed below. 
 
1.1.2.1. P fimbriae 
 
P fimbriae are encoded by the pap gene cluster. The adhesin, PapG is located on the tip 
of the fibrillum, and it mediates the attachment to the uroepithelium. The host cell receptors for 
P fimbriae are globoseries of glycosphingolipids (GSLs), which are expressed on uroepithelial 
cells. These receptors are abundant on the uroepithelial [13], but their expression varies 
depending on the P blood group [14].  
P fimbriae are classified according to their iso-receptor specificity. Class I P fimbriae 
carry PapGJ96 adhesin, which binds to globotriaosylceramide (GbO3). The association of this 
allele to UTIs is unknown [15], and it is uncommon in clinical isolates. Class II P fimbriae have 
been shown to have a strong association with acute pyelonephritis in both children [16] and 
adult women [17]. The PapGIA2 adhesin binds to most members of the globoseries of GSLs or 
GbO4, and recognize all P blood group determinants. Class III G adhesins, encoded by the 
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PrsGJ96 sequences, binds to sheep erythrocytes or GbO5, and recognize P blood group 
determinants with a terminal blood group A residue [16, 18]. This allele is the predominant 
variant in women with first-episode or recurrent acute cystitis [19]. A fourth PapG allele was 
recently discovered, the receptor and the significance in UTIs are still unknown [20]. 
 In epidemiological studies P fimbriae have shown the strongest association with acute 
disease severity, with at least 90% of acute pyelonephritis but less than 20% of ABU strains 
expressing this phenotype [13, 21, 22].  
 
1.1.2.2. Type 1 fimbriae 
 
 Type 1 fimbriae are encoded by the fim gene cluster, and are the most abundant adhesion 
factors on E. coli. The adhesin FimH is situated along the shaft and at the top of the fimbriae. 
Type 1 fimbriae recognize mannose on secreted and cell bound proteins, and bind to β-1 and α-
3 integrins [23], Tamm-Horsfall protein, secretory immunoglobulin A and the mannose-
containing CD48 receptor on mast cells. In vitro studies have shown that upon type 1 fimbrial 
binding to uroplakins the bacteria invade the underlying immature cells, and form intracellular 
bacterial communities [24]. 
Studies on the role of type 1 fimbriae as a colonization factor in the human urinary tract 
have provided contradictory results.  As most E. coli isolates carry the fim operon regardless of 
their source [25], the expression of the type 1 fimbriae, or possession of the fim gene cluster 
has not convincingly shown to correlate with uro-pathogenicity in humans [8, 13, 22]. On the 
other hand, the expression of type 1 fimbriae was shown to characterize the most virulent 
members of a single clone (O1:K1:H7) and a deletion of the fim gene cluster from that 
background was shown to attenuate virulence in the murine UTI model [26].  
 
1.1.2.3. S fimbrial family 
 
Members of the S-fimbrial family of adhesins consists of S-fimbriae (sfa), with its 
subtypes sfaI and sfaII; F1C-fimbriae (foc); S/F1C-related fimbriae (sfr) [27] [28] and AC/I-
fimbriae (fac). S-fimbrial adhesins recognize α-sialyl-2-3-β-lactose-containing receptors and 
are predominantly expressed by strains responsible for meningitis and sepsis but they have been 
described in strains causing UTIs as well [28, 29], whereas F1C-fimbrial adhesins bind to β-
GalNac-1,4-β-Gal-containing structures [30] and are preferentially expressed by UTI isolates 
[28]. 
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1.1.2.4. Flagella 
 
Flagella are filamentous structures attached to the surface of the bacteria. The flagellar 
filament is a polymer of flagellin subunits encoded by the fliC gene [31]. The filament is rotated 
by a motor apparatus in the plasma membrane [32] thus increasing bacterial motility. Flagella 
have been proposed to increase bacterial virulence by providing a selective advantage in the 
fight for nutrients in the urine and enhance bacterial dissemination to the upper urinary tract 
[33]. 
 
1.1.2.5. Biofilm 
 
A biofilm is a structured community of microorganisms encapsulated within a self-
developed polymeric matrix adherent to a surface [34]. In the urinary tract the formation of 
biofilm may protect bacteria against environmental stress, phagocytosis and antibiotics. Curli 
are bacterial surface organelles that bind several host extracellular matrix and contact phase 
proteins. These adhesive fibers enhance bacterial biofilm formation on various abiotic surfaces. 
In vitro, isolates causing asymptomatic bacteriuria formed biofilm more readily than isolates 
from acute pyelonephritis [35]. 
 
1.1.2.6. Lipopolysaccharide 
 
Lipopolysaccharides (LPS) can be found in the outer membrane of Gram-negative 
bacteria. LPS is composed of 3 covalently linked components: outer carbohydrate chains of 1-
50 oligosacharide units called the O antigen or O-specific side-chain; a core oligosaccharide; 
and an interior disaccharide with multiple fatty acids, called lipid A, which is responsible for 
much of the toxicity of Gram-negative bacteria (endotoxin).  Some O antigen serotypes (i.e. 
O1, O2, O4, O6, O7, O8, O16, O18, O25, O50 and O75) were shown to be frequent among 
UPEC strains [36]. LPS interact with other virulence factors (e.g. LPS-dependent targeting of 
HlyA to host cell membranes) and may also play a role in the protection against the human 
immune system [37].  
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1.1.2.7. Siderophore systems 
 
Bacteria need iron ions to successfully colonize the urinary tract. Bacteria express 
siderophores that scavenge iron from the environment to overcome iron limitation in the host 
[37]. E. coli strains may express different types of siderophores. Aerobactin is frequent in UPEC 
isolates, as it was shown to be present in about 45% of symptomatic isolates [38], but multiple 
systems may be expressed during colonization. Siderophore receptors may have dual functions, 
as the salmochelin siderophore receptor IroN also functions as an internalization factor 
promoting the invasion of urothelial cells by UPEC in vitro [39]. 
 
1.1.2.8. Toxins 
 
Many UPEC secrete toxins that facilitate infection by damaging host tissues or by 
disabling the host immune system. The α-hemolysin (HlyA) is a pore-forming toxin, which is 
encoded by about 30-50% of UPEC isolates [37, 40]. The expression of α-hemolysin was shown 
to increase the clinical severity of urinary tract infections [40]. In high concentrations, α-
hemolysin leads to cell lysis [41, 42], however, sublytic concentrations seem to be more 
physiologically relevant, when α-hemolysin was proposed to inhibit chemotaxis and 
phagocytosis as well as stimulation of host apoptotic and inflammatory pathways [37, 43, 44]. 
Cytotoxic necrotizing factor 1 (CNF1) is present in about 30% of UPEC strains [40]. 
CNF1 activates Rho GTPases in the host cell [45], promotes apoptosis of bladder epithelial 
cells [46] and counteracts phagocytic activity and chemotaxis of polymorphonuclear 
neutrophils (PMNs) [47].  
 
1.1.2.9. TIR domain containing proteins 
 
Toll/interleukin-1 receptor (TIR) domain containing proteins (Tcps) are soluble proteins 
which inhibit Toll-like receptor (TLR) signaling. Tcps are homologues of the Toll/Interleukin-
1 receptor domain, and are secreted by virulent bacteria. TcpC promotes bacterial survival by 
inhibiting the innate host response and specifically MyD88 dependent signaling pathways. 
TcpC was shown to be clinically relevant as a virulence factor in UTIs with severe kidney 
infections, and promoted renal tissue damage in murine models of UTI [48].  
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1.1.3. Host response induction 
 
The urinary tract relies primarily on innate immunity for its defense [49]. UPEC 
pathogenesis initiates with bacterial attachment to superficial bladder epithelial cells. The 
attachment is recognized by the cells, and triggers intracellular signaling proteins, transcription 
of target genes and release of effector proteins [50, 51] (Figure 1). TLR4 signaling is crucial 
for recognition of E. coli in the urinary tract, and may be activated via binding P fimbriae or 
type 1 fimbriae to uroepithelial receptors, which trigger different signaling pathways [51, 52]. 
The activated epithelial cells secrete chemokines (Interleukin [IL]-8), cytokines (IL-6, tumor 
necrosis factor [TNF]) and antimicrobial peptides (LL-37) depending on the activated signaling 
pathway. IL-8 is a strong chemoattractant for PMNs, its attachment to its receptors CXCR1 and 
CXCR2 on PMNs results in neutrophil recruitment and migration across the uroepithelium, and 
eventually the clearance of infection.  
The same cells respond poorly to asymptomatic carrier strains and proinflammatory 
pathways are not activated but suppressed [53]. This unresponsiveness is probably essential to 
protect the host from constant innate immune activation and to permit the symbiotic relationship 
between bacteria and host to develop into the commensal like and protective state of ABU. 
 
 
 
 
Figure 1. Host response induction in the urinary tract 
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1.2. Deliberate establishment of asymptomatic bacteriuria  
 
1.2.1. Asymptomatic bacteriuria 
 
Patients with asymptomatic bacteriuria (ABU) may carry more than 105 cfu/ml of 
bacteria in their urine for months or years without developing symptoms or sequels [54]. ABU 
was generally considered as a harmful state until the 1970’s, and it was aggressively treated 
accordingly. In the next decades, more and more publications showed that ABU is actually a 
harmless condition in patients without risk factors [55]. Furthermore, Hansson and co-workers 
showed in pediatric populations that ABU may be protective against recurrent episodes of UTIs 
[56], as children with long time asymptomatic bacteriuria developed symptomatic infections 
more often, when they were treated from ABU. This beneficial effect has been attributed to 
bacterial interference by competition for nutrients and by bacterial production of toxic 
molecules [57]. ABU creates a special form of colonization resistance in the urinary tract, 
similarly to the intestinal or vaginal microflora, thus it can prevent superinfections with more 
virulent strains.   
  
1.2.2. Escherichia coli 83972 
 
Bacteria causing ABU differ from bacteria causing symptomatic infections.  E. coli 
83972 was first isolated in schoolgirls with ABU [55]. It is a non-fimbriated strain belonging 
to a non-pathogenic OKH serogroup (OR:K5:H-)[55] and a  phylogenetic lineage B2 of E. coli, 
indicating a close relatedness to the UPEC strains which cause symptomatic UTI [58]. 
The strain has been fully sequenced and extensively studied. E. coli 83972 carries the 
different virulence genes, but does not express them, and never has been shown to express 
functional adhesion properties. It has a large deletion in the fim gene cluster and several point 
mutations in the papG adhesin, rendering both type 1 and P fimbriae unable to adhere, thus 
capable of colonizing the urinary tract for a long period. It carries a 1.6 kb plasmid, which is 
stable, and can be used for strain identification [59, 60]. E. coli 83972 was initially classified as 
O- and K antigen negative, due to weak surface antigen expression. Based on genome sequence 
analysis [61], an O antigen determinant which in part represents so far unknown DNA 
sequences and a  group II capsule determinant coding for the K5 capsular type was identified. 
Analysis of the LPS O side-chain pattern demonstrated that E. coli 83972 lacks long O antigen 
side chains, explaining why it was initially classified as O-negative. 
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1.2.3. Inoculation studies 
 
The idea of deliberately established bacteriuria of the lower urinary tract was born based 
on the observations regarding the protective effect of ABU in Lund, Sweden. E. coli 83972 was 
chosen for the purpose of colonization. The first colonization studies showed that the deliberate 
establishment of asymptomatic bacteriuria is a safe procedure without side effects, and long 
term asymptomatic bacteriuria can be achieved in patients with residual urine [59]. The 
presence of residual urine facilitates the development of stabile bacteriuria, and it is usually 
required for the successful colonization of the bladder.  
In 2010 a prospective randomized, controlled study of bacterial colonization was carried 
out [62]. In this study the authors compared the time to the first UTI and the total number of 
UTIs in during 12 months in the same patients with and without E. coli 83972 bacteriuria 
(inoculated with saline only). The authors found that the time to the first UTI was significantly 
longer with than without E. coli 83972 bacteriuria (median 11.3 vs 5.7 months, p < 0.0129).  
Also, there were significantly fewer UTI episodes during 12 months in the bacteriuria group 
compared to the placebo group (13 vs 35 episodes, p < 0.009). There was no febrile UTI episode 
in either of the study arms and no significant side effects of intravesical inoculation were 
reported. 
 
1.2.4. Deliberately established asymptomatic bacteriuria as a research model 
 
The deliberate establishment of asymptomatic bacteriuria is not only a method for 
prevention, however. It creates a unique situation, where we have an extensive knowledge of 
both the pathogen and the host, and we also control the time of the infection. With this model 
of controlled uroinfection we can monitor the pathogen-host interactions in the human urinary 
tract, which gives us countless research opportunities regarding the molecular basis of UTIs. 
The results of the colonization studies showed that colonized asymptomatic patients 
have a slightly elevated levels of neutrophils and cytokines in their urine, representing a low, 
but significant local host response. Interestingly, the rate of the host response varies between 
patients, they can be grouped as low or high responders. However, the same individual 
characteristic response can be observed for each patient during repeated colorizations [63].  
Analysis of the bacterial isolates regained from colonized patients in different time 
points after colonizations provided the first, genome-wide example of a single bacterial strain's 
16 
 
evolution in different human hosts. The results showed different bacterial genetic changes in 
case of each colonized patients, proving that each host “personalizes” their microflora, and that 
this adaptive bacterial evolution points towards commensalism rather than virulence [61]. 
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2. AIMS 
 
Our major aim was to analyze the role of bacterial virulence factors in the clinical course 
and outcome of urinary tract infections caused by Escherichia coli. 
 
With the analysis of Escherichia coli 83972 strains isolated from symptomatic episodes during 
deliberately established E. coli 83972 bacteriuria we aimed to (Paper I): 
 
- Investigate if a reversion to a functional virulence gene repertoire by these isolates may 
account for the switch from asymptomatic carrier state to symptomatic lower urinary tract 
infections. 
- Identify changes in the bacterial genome of E. coli 83972 strains isolated during 
symptomatic episodes. 
- Assess the safety of the method of deliberately established ABU by investigating the 
potential of the colonizing bacteria to reacquire virulence. 
  
With the virulence factor analysis of clinical Escherichia coli isolates from urinary tract 
infections we aimed to investigate (Paper II): 
 
- If Escherichia coli strains causing acute cystitis can be characterized by a distinct virulence 
factor repertoire. 
- If the virulence factor profile of E. coli strains causing acute cystitis can be distinguished 
from the virulence factor profile of the strains causing acute pyelonephritis. 
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3. MATERIAL AND METHODS 
 
3.1. Analysis of E. coli 83972 strains isolated from symptomatic episodes 
during deliberately established bacteriuria 
 
We investigated E. coli 83972 re-isolates from symptomatic UTI episodes of patients 
colonized in a previously published human inoculation study (Trial ID number: RTP-A2003 - 
International Committee of Medical Journal Editors [https://register.clinicaltrials.gov]. [62]. 
Patients with incomplete bladder emptying due to spinal or lower motor neuron lesions who 
had recurrent lower UTIs were included in this placebo controlled study of intravesical 
inoculation with E. coli 83972. The human ethics committee at Lund University approved the 
study and patients gave their informed consent. The study design, patient characteristics and 
clinical results are described in detail in the paper by Sundén et al [62]. 
 
3.1.1. Inoculation protocol 
 
Before inoculation pre-existing bacteriuria was eliminated by antibiotic treatment, and 
after an antibiotic-free interval urine was cultured to confirm sterility. The patients were 
catheterized (14 Ch. Low-Fric - Astra), and after complete evacuation of the bladder, 30 ml of 
the bacterial suspension of E. coli 83972 (105 cfu/ml) was injected, and the catheter removed. 
The procedure was repeated once daily for 3 days. 
 
3.1.2. Symptomatic urinary tract infection episodes 
 
We examined the subset of colonized patients in whom symptomatic UTI episodes 
developed. Patients defined UTI episodes with a previously developed self-reported method 
[64], and UTI were also determined in a structured interview and by urine culture yielding 
greater than 105 cfu/ml of a single organism. Symptomatic episodes were defined by at least 2 
symptoms, including suprapubic pain, dysuria and/or frequency as well as increased spasticity 
in patients with a spinal cord lesion.  
 
3.1.3. Bacteria, cytokines and DNA Techniques 
 
E. coli 83972 re-isolates were identified by polymerase chain reaction (PCR) using 
primer pairs that matched the cryptic 1.6 kb plasmid and the internal 4,253 bp fim deletion. For 
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in vitro analysis strains were grown in lysogeny broth (LB) or in pooled human urine with or 
without 1.5% agar (DifcoTM). 
Neutrophils were quantified in uncentrifuged urine using a hemocytometer chamber. 
We quantified IL-6 and 8 concentrations by Immulite® assay. 
Qiagen® products were used for genomic DNA isolation. Primers were obtained from 
Eurofins MWG/Operon, Ebersberg, Germany. Restriction enzymes were obtained from New 
England Biolabs®. Genomic DNA was analyzed by pulsed field gel electrophoresis.  
Phylogenetic classification of the re-isolates was done according to the results of a 
triplex PCR using a method described by Clemont et al [65]. 
 
3.1.4. Bacterial genotypes 
 
The detection of fitness- and virulence-associated genes of extraintestinal pathogenic E. 
coli (ExPEC) included type 1 fimbrial (fim), P fimbrial (pap), F1C fimbrial (foc) gene clusters, 
the genes coding for the toxins alpha-hemolysin (hlyA) or cytotoxic-necrotizing factor (cnf1), 
the yersiniabactin siderophore receptor (fyuA), the salmochelin siderophore receptor (iroN), the 
aerobactin siderophore (iuc) as well as the K5 capsule (kpsMT K5) determinant and the 
pathogenicity island marker malX.  Genotyping was performed by PCR using primers that 
matched unique regions of the gene sequences [28, 58, 66]. 
 
3.1.5. Phenotypic assays 
 
Type 1 fimbrial expression was detected by hemagglutination of guinea pig and human 
erythrocytes after in vitro passage in Luria broth. Agglutination was performed both in the 
presence and absence of α-methyl-D-mannoside. Strains causing mannose sensitive 
agglutination were defined as type 1 fimbriated [67].  
P- and S/F1C fimbriae were detected by hemagglutination of defibrinated human and 
bovine erythrocytes, respectively. Aliquots of bacterial overnight cultures in LB or pooled 
human urine were incubated with a suspension of human or bovine blood (Elocin lab, Munich). 
Hemagglutination was compared after incubation for some minutes on ice. UPEC strain 536 
was used as a positive and E. coli strain HB101 as a negative control. 
Hemolytic activity was detected on sheep blood agar plates (Oxoid) after overnight 
incubation at 37 °C as the formation of clear halos around the colonies. UPEC strain 536 was 
used as a positive and E. coli strain HB101 as a negative control. 
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The aerobactin siderophore was detected by the aerobactin cross-feeding bioassay [68]. 
109 cells of aerobactin-requiring indicator E. coli strain LG1522 were cultured in M9 soft agar 
containing 200 mM 2’-2’-dipyridyl (Sigma, Deisenhofen, Germany). Aerobactin production by 
the test strains was indicated by a zone of enhanced growth of E. coli LG1522 around the 
colonies of the test strains. E. coli ABU strain 83972 was used as a positive and E. coli strain 
HB101 as a negative control. 
Morphotype analysis on Congo red and Calcoflour plates was used to study curli fimbria 
and cellulose expression [69].   
 
3.1.6. Biofilm formation 
 
Biofilm formation was assessed in a microtiter plate assay modified after O’Toole and 
Kolter [70]. Bacteria were grown overnight in LB medium at 37 °C with agitation. Filter-
sterilized pooled human urine was then inoculated (1:100) with the overnight bacterial culture 
and 160 μl of this inoculum was pipetted into 96-well U-bottom flexible microtiter plates (8 
wells per strain). Microtiter plates were incubated statically at 37 °C for 48 h. Afterwards, the 
medium was removed and the microtiter plates were washed twice with 1% PBS followed by 
drying at 65 °C for 10 min. The plates were then stained with 0.1% crystal violet for 10 min. 
Next, plates were washed twice with 1% PBS and dried at 65 °C for 10 min. Absorbed crystal 
violet was eluted using 180 μl acetone-ethanol (1:5), pooled and diluted 1:10. Finally, optical 
density was measured at 580 nm. Biofilm assays were performed at least in triplicate. 
 
3.1.7. O antigen side chain analysis 
 
Isolation of LPS from the E. coli strains used in this study was performed as previously 
described by Grozdanov et al [71]. 
 
3.1.8. Motility  
 
Overnight cultures were stabbed into the middle of motility agar plates (LB 
supplemented with 0.3% w/v agar). Plates were incubated for 16 h at 37 °C. Motility was then 
assessed by inspection of the migration zone of the bacteria. Three independent experiments 
were performed with three individual colonies per strain. 
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3.1.9. Bacterial growth in pooled human urine 
 
Growth of the bacterial isolates was compared to E. coli 83972 wild type by growing 
them without agitation in pooled human urine overnight and inoculating 30 ml fresh medium 
the following day with the overnight culture. Optical density was measured at 600 nm every 
hour for 8 h and overnight. The experiment was repeated three times using different batches of 
pooled human urine.  
 
3.1.10. Gene expression profiling 
 
RNA preparation and microarray hybridisation was performed as previously reported 
[61]. For total RNA isolation, the strains were grown statically in pooled human urine at 37 °C 
until they reached mid-logarithmic phase. Samples were then treated with RNAprotect (Qiagen) 
and extracted using the RNeasy mini kit (Qiagen). DNA traces were removed by RNase-free 
DNase I (New England Biolabs).  
For expression profiling, custom-tailored oligonucleotide microarrays (Operon 
Biotechnologies) were used. 10 μg of total RNA were reverse transcribed (SuperScript III, 
Invitrogen) with direct incorporation of fluorescently labelled (Cy3- or Cy5-) dCTP (GE 
Healthcare). 160 pmol of each Cy-3 and Cy-5 labelled probe were used for hybridisation. For 
each experiment, at least three independent hybridizations were performed. Hybridized and 
washed slides were scanned using a GenePix 4000B Microarray Scanner (GE Healthcare) with 
a resolution of 10 μm pixel size.  
The data was further analyzed with Acuity 4.0 (Molecular Devices) including 
normalization by a linear ratio-based method. For statistical significance, one sample t-test was 
applied with Bonferroni correction. For data analysis, a cut-off value of 1.7 (ln2) was used with 
p<0.09. Hierarchical clustering and visualization of expression patterns was performed with 
CLUSTER and TREEVIEW [72], respectively. 
 
3.1.11. In vitro cell experiments 
 
The human kidney carcinoma A498 (ATCC HTB-44) and T24 bladder carcinoma cell 
lines were grown in RPMI 1640 supplemented with 1 mM sodium pyruvate, 1 mM non-
essential amino acids, 50 mM/ml gentamicin, and 10% fetal calf serum (FCS - PAA 
22 
 
Laboratories, Pasching, Austria). Cells were maintained at 37 °C + 5% CO2 in a humidified 
atmosphere and split weekly.   
For adhesion studies 109 cells were exposed to 105 bacteria (E. coli 83972 wild type, the 
symptomatic re-isolates from the patients and CFT073 as positive control) for 45 minutes. After 
washing adhesive bacteria were counted and microscopic pictures were taken. 
For host response experiment cells were exposed to E. coli 83972 wild type, the 
symptomatic re-isolates or CFT073 (108 cfu in 0,01 mL) diluted in 1 mL media with 5% FCS 
or without FCS. Supernatants were collected 6 and 24 hours after stimulation and the secreted 
cytokines (IL-6 and IL-8) were quantified by Immulite 100 (Siemens, Bad Nauheim, Germany).  
 
3.1.12. Experimental animal infections 
 
Experiments were performed with the permission of the animal experimental ethics 
committee, Lund District Court, Sweden. Female C3H/HeN mice bred at the MIG animal 
facility were used at age 6 to 12 weeks.  After anesthesia (Isofluorane), mice were infected by 
intravesical inoculation with E. coli 83972 wild type and the symptomatic re-isolates (109 cfu 
in 0.1 mL) through a soft polyethylene catheter (outer diameter 0.61 mm; Clay Adams, 
Parsippany, NJ, USA). Animals were sacrificed at 6 hours, 24 hours and 7 days while under 
anesthesia, and the kidneys and bladders were removed. Viable counts in homogenized tissues 
were determined after overnight growth on tryptic soy agar plates at 37 °C. Urine samples 
collected prior to and daily after infection were cultured and recruited neutrophils were 
quantified in uncentrifuged urine by use of a hemocytometer.  
 
3.2. Virulence factor analysis of clinical Escherichia coli isolates from urinary 
tract infections  
 
We examined the virulence factor repertoire of Escherichia coli strains prospectively 
isolated from women with community-acquired acute cystitis. The course of UTIs and upper 
urinary tract involvement were documented.  
 
3.2.1. Patients, UTI episodes 
 
Women > 18 years of age with symptomatic UTI were enrolled in the analysis. They 
had significant bacteriuria, defined as ≥ 104 cfu/ml. Patients were diagnosed with acute cystitis 
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based on the following symptoms: frequency, dysuria and/or suprapubic pain, a temperature 
<38.0 °C and no flank pain. Patients who also had flank pain and/or fever were diagnosed as 
having acute cystitis with upper urinary tract involvement. The UTI episode was classified as 
sporadic (<two episodes during the previous six months or <three during the previous 12 
months) or recurrent. The history of previous UTI, concomitant disease and medical treatment 
were recorded. Blood samples were obtained at diagnosis and examined for C reactive protein 
(CRP, cut off ≥ 10 mg/l) and white blood cell counts (cut off ≥ 10x109/l). 
 
3.2.2. Urine cultures 
 
Midstream urine samples were obtained at diagnosis. Quantitative urine cultures 
identified 247 E. coli growing as monocultures, and the isolates were stored in deep agar stabs. 
For analysis, bacteria were grown overnight on tryptic soy agar plates at 37 °C. 
 
3.2.3. Bacterial genotypes, phenotypes and hemolysin production 
 
We genotyped the gene sequences coding the virulence factors (pap gene cluster - 
papGIA2, prsG J96; fim; TcpC). The genotypes were defined by PCR, using primer pairs that 
matched unique regions of the adhesin sequences [48, 73].  
The expression of type 1 and P fimbriae, curli and cellulose, as well as biofilm formation 
was determined as described previously.   
Hemolytic strains were identified in nutrient agar with 5% washed horse erythrocytes 
after overnight incubation. A hemolytic zone larger than the overlying colony was considered 
positive [74]. 
 
3.2.4. Statistical analysis 
 
Chi-square test or the Fisher’s exact test was used. P <0.05 was considered statistically 
significant (two-tailed). 
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4. RESULTS 
 
4.1. Analysis of E. coli 83972 strains isolated from symptomatic episodes 
during deliberately established bacteriuria 
 
4.1.1. Symptomatic UTI episodes during E. coli 83972 bacteriuria 
  
In the placebo controlled colonization study by Sundén et al, the number of symptomatic 
UTI episodes was significantly reduced in patients inoculated with E. coli 83972 compared to 
the  placebo control group (inoculated with saline only) or to the patients previous condition 
before the study. A small group of the patients with E. coli 83972 bacteriuria developed 
symptomatic UTI, however. Before the symptoms developed these patients carried E. coli 
83972 asymptomatically without discomfort. The reported UTI episodes were non-febrile lower 
urinary tract infections and antibiotic treatment resulted in prompt symptom relief.  
Out of the 20 patients, who spent a total of 202 months (mean 10.1) with E. coli 83972 
bacteriuria 13 symptomatic episodes were reported in nine patients. In 10 cases super-infection 
was caused by a different E. coli strain (n=7), Pseudomonas aeruginosa (n=1), Enterococcus 
faecalis (n=1) or Proteus mirabilis (n=1).  E. coli 83972 infection was verified in three cases, 
two of which occurred in one patient. In patients R4 and R15 only E. coli 83972 was recovered 
during 1 and 2 symptomatic episodes, respectively, suggesting that the symptomatic episodes 
were caused by the colonizing strain. The 3 symptomatic episodes were accompanied by 
elevated urine cytokine levels (IL-6 and IL-8), and increased urine polymorphonuclear 
leukocyte numbers indicating a significant host response. 
To examine if a change in bacterial properties had precipitated the symptomatic episode, 
the three E. coli 83972 isolates were further examined. In addition, we included two E. coli 
83972 isolates from symptomatic episodes in patients not included in the previously published 
study. One from patient R10, who carried E. coli 839972 after the closure of the study for a 
total of 104 days, when he had a symptomatic infection, and one from patient Sp10, who was 
successfully colonized with E. coli 83972, and who developed symptoms after 67 days of E. 
coli 839972 bacteriuria, but who was excluded from the study due to steroid treatment. Thus, a 
total of 5 symptomatic re-isolates were included in the analysis (Table 1). 
The re-isolates were verified as E coli 83972 by identification of the cryptic 1.6 kb 
plasmid and the internal 4,253 bp fim deletion. Genomic restriction patterns of all re-isolates 
were defined by pulse field electrophoresis and were found to be identical to E coli 83972. 
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  Pt R15 (episode No.)   
 Pt R4 1 2 Pt R10 Pt Sp10 
Gender F F F F M 
Age 60 46 46 47 67 
Diagnosis 
Detrusor 
insufficiency, 
post-void residual 
urine 
Detrusor 
insufficiency, 
post-void residual 
urine 
Detrusor insufficiency, 
post-void residual 
urine 
Spinal lesion, 
neurogenic 
bladder disorder 
UTI episode:      
Days after inoculation 192 20 19 104 67 
Symptoms 
Suprapubic pain, 
dysuria, frequency 
Local discomfort, 
dysuria, frequency 
Suprapubic pain, 
dysuria, frequency 
Local discomfort, 
dysuria, 
increased spasticity 
F= female M=male 
 
    
 
Table 1. Characteristics of 4 patients with E. coli 83972 asymptomatic bacteriuria and total of 5 proven UTI 
episodes caused by E. coli 83972 
 
 
4.1.2. Virulence properties of the symptomatic re-isolates 
 
The re-isolates were characterized regarding virulence genes associated with 
extraintestinal pathogenic E. coli. All of the re-isolates carried the examined gene sequences. 
The re-isolates were also examined for the expression of virulence factors. The strains did not 
express functional P, type 1, or F1C fimbriae. To exclude that E. coli 83972 had acquired new 
adhesins the re-isolates were incubated with human uroepithelial cells (A498 kidney cells and 
T24 bladder cells). The re-isolates, such as the wild type failed to adhere to the human cells 
(Figure 2). There was no consistent change in biofilm, curli or cellulose formation. Re-isolates 
expressed an O antigen pattern identical to that of E. coli 83972. 
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Figure 2. Adhesion to T-24 bladder epithelial cells and A498 kidney epithelial cells. No difference in adhesion 
capacity between the wild type and the re-isolates. 
 
 
4.1.3. The presence of heterogeneous phenotypes 
 
Further phenotypic assays were performed to identify differences in the expression of 
bacterial traits that might influence survival in the urinary tract. Growth rates in urine were 
monitored and compared to growth in Luria broth. No increase was observed in growth rates 
compared to the E. coli 83972 wild type, however re-isolates of samples R15-1 and R15-2 
showed heterogeneous phenotypes and comprised colonies of different sizes or motility.  
For colonies from urine sample R15-1 about 75% the colony size and morphology 
resembled those of strain E. coli 83972 (R15-1 clone I). The remaining colonies (R15-1 clone 
II) were small, and these variants grew more slowly in liquid medium than E. coli 83972 wild 
type. These colonies were also identified as E. coli 83972 with the analysis of the specific 
plasmid, fim deletion, restriction pattern and virulence genes. The slow growth and reduced 
colony size were reminiscent of small colony variants associated with persistent infection. 
Individual colonies of urine sample R15-2 differed in motility and flagella expression. 
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4.1.4. Motility 
 
 Motility has been proposed to be an important virulence factor, as flagella enhance the 
ascent of bacteria from the lower urinary tract to the kidneys [75]. Motility of the strains was 
therefore screened on swarming agar plates and compared with the E. coli 83972 wild type. We 
observed an increase in motility in two of the re-isolates, R15-2 and Sp10. While Sp10 was a 
100% motile re-isolate, R15-2 appeared as a phenotypically heterogeneous population with 
individual cells displaying increased motility (R15-2 clone I), while the motility of the 
remaining cells (R15-2 clone II) did not differ from the E. coli 83972 wild type (Figure 3). The 
increase in motility reflected increased expression of flagella as shown by Western Blot 
analysis.  
 
 
 
Figure 3. Motility of E. coli 83972, the symptomatic re-isolates and CFT073 as positive control on urine 
swarm agar plates 
 
Whole genome transcription analysis was conducted to compare the transcriptional 
profile of E. coli 83972 to the motile re-isolates (R15-2 clone I and Sp10).  There were 95 de-
regulated genes in case of R15-2 clone I. 80 genes were up-regulated and 15 were down-
regulated. Most up-regulated genes encoded bacteriophage components, and genes were also 
involved in the stress response, including recA, recN, lexA, ruvB, dinI, dinB, sulA, yebG and 
umuD, and sigma factor expression (rpoA, rpoE and rpoS). In addition, acid stress response 
genes (gadA, gadB, hdeAB, cadB and slp) were up-regulated. In contrast, a group of genes 
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involved in phosphotransferase transport were down-regulated. In this re-isolate flagellar gene 
expression was less pronounced. 
 In Sp10 from the 98 de-regulated genes 81 were up-regulated and 17 were down-
regulated. In this 100% motile re-isolate genes involved in flagella biosynthesis and assembly 
(flgA, flgDEFG, flhA, fliA, fliG and fliO) was found to be significantly up-regulated. Other 
upregulated genes were involved in heat shock response (groEL and groES), LPS biosynthesis 
(rfaGPIJY, waaV, waaW, lpxAB), amino sugar utilization (glmUS), and iron-uptake 
(chuATUWXY and entCA). Significantly down-regulated genes were involved in N-acetyl-D-
galactosamine (aga), sorbitol (srl) and galactonate (dgo) transport. 
Few de-regulated genes were shared by the two re-isolates. Genes up-regulated in both 
R15-2 and Rp10 were involved in biofilm formation (yjbE, yqjD), D-glucarate utilization 
(gudD, gudP) and in the synthesis of proteins of the 30S and 50S ribosomal subunits. Ribose 
ABC transporter genes were down-regulated in both re-isolates relative to the wild type (Figure 
4). 
 
 
Figure 4. Gene expression profiling of the motile re-isolates. A, gene expression in re-isolates relative to E. coli 
83972. Most regulated genes were unique to each isolate. B, hierarchical cluster analysis of deregulated genes in 
re-isolates relative to E. coli 83972. Values represent mean expression ratio of at least 3 independent microarray 
experiments. Green areas indicate significantly regulated (log twofold change, p <0.05) suppressed genes. Red 
areas indicate significantly regulated (log twofold change, p <0.050) up-regulated genes. Black areas indicate 
genes without statistically significant change (p >0.05). 
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4.1.5. Host response induction by the re-isolates 
 
To analyze the re-isolates capacity to induce host response, we performed in vitro host 
response experiments in A498 human kidney cells. The IL-6 and IL-8 secretion in A498 cells 
exposed to the symptomatic re-isolates for 24 hours did not differ significantly from the 
response of the cells exposed to E. coli 83972 wild type (Figure 5). 
 
 
 
 
Figure 5. Epithelial response to in vitro infection of A498 cells with E. coli 83972 wild type, symptomatic re-
isolates and uropathogenic E. coli strain CFT073. Geometric means ± SEM of two independent experiments. 
 
 
 
Next we performed experimental urinary tract infections with the re-isolates and E. coli 
83972 wild type in C3H/HeN mice to further investigate if the symptomatic re-isolates 
reacquired increased virulence. There were no major difference in the bacterial clearance 
between the strains compared to the wild type, in respect of the bacterial counts in urine, kidneys 
and bladders or mortality. No symptoms appeared in any group. The kinetics of neutrophil 
recruitment did not differ between the groups. The level of neutrophils in the urine reached its 
maximum at 6 hours, and then decreased and remained low until day 7, reflecting a low acute 
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inflammatory response to E. coli 83972. Motility of the re-isolates did not influence bacterial 
numbers or urine neutrophil counts (Figure 6). 
 
 
 
 
Figure 6. Experimental infection of C3H/HeN mice by intravesical inoculation with 109 cfu in 0.1 ml E. coli 
83972 or re-isolates from symptomatic episodes. Bacterial number in urine, kidneys and bladders, and neutrophil 
response revealed no difference in virulence. 
 
 
 
4.2. Virulence factor analysis of clinical Escherichia coli isolates from urinary 
tract infections 
 
4.2.1. Patient characteristics 
 
247 women with microbiologically proven uncomplicated urinary tract infections were 
included in the analysis (mean age 51 years, range 18 - 91) and their infecting E. coli strains 
were saved. 242 patients (98%) had bacteriuria ≥105 cfu/ml, in 5 cases patients had 104 cfu/ml 
of urine. 215 patients were diagnosed with acute cystitis only, while 32 patients (13%) also had 
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upper urinary tract involvement. This group had significantly increased CRP levels and white 
blood cell counts compared to the acute cystitis group (p = 0.01 and p = 0.01 respectively). The 
infection was sporadic in 180 cases, while 67 women had recurrent infection. 
  
4.2.2. Virulence factor genotypes and expression 
 
Fim sequences coding type 1 fimbriae were present in 96% of the isolates and type 1 
fimbrial expression was detected in 80%. There was no significant difference between isolates 
from patients with acute cystitis (81%) and patients with upper urinary tract involvement (71%) 
(Figure 7A). 
Hemolysin expression was only detected in 28% in the total sample and the frequency 
did not differ between the two groups. 
Curli fimbriae were detected in 75% of all the cases (73% in case of acute cystitis and 
89% in patients with upper tract involvement) and 13% of the strains formed cellulose (14% 
vs. 10%).  There were no significant differences between the subgroups. However, only 16% 
of all patients formed biofilm, 15% of cystitis patients and 24% of patients with upper UTI, 
with no significant difference between the subgroups (Figure 7B). 
The pap gene cluster was detected in 43% of all isolates (papGIA2 24%, prsGJ96 20%, 
both 3%). The pap genotype was more common in the isolates from patients with upper urinary 
tract involvement (56%) compared to the acute cystitis group (41%), although the difference 
was not significant (Figure 7C and D). P fimbrial expression (Class II + III) was present in 42% 
of the isolates. Among those, Class II fimbriae -papGIA2- were more common (77%) than Class 
III fimbriae -prsGJ96- (23%) (Table 2).  P fimbrial expression was more common in case of 
upper tract involvement (50%) compared to isolates from patients with acute cystitis (41%), 
however the difference was not significant (p=0.332). There was no difference in Class II 
distribution among patients with acute cystitis with or without upper tract involvement (76% 
versus 81%, p = 0.75).  
TcpC was expressed by 33% of the isolates, and it was significantly more common in 
the upper urinary tract involvement group (32% vs. 42%, p<0.01). TcpC was also significantly 
more common in case of papG+/prsG+ strains compared to those lacking these sequences 
(Figure 7E and F).  
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Figure 7. Virulence factor repertoire of Escherichia coli isolates from women with acute cystitis. (A) Fim 
genotype and type 1 fimbrial expression (B) Curli, cellulose expression and biofilm formation (C) and (D) Pap 
genotype and P fimbrial expression (E) TIR homologous TcpC sequences in the different patient groups, (F) and 
in relation to the pap genotype. 23 isolates were weakly positive and are not included. Significantly higher TcpC 
frequency in patients with papG+ and/or prsG+ strains. 
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Pap genotype and 
P fimbrial expression 
No. of isolates (%) 
P values 
All isolates Cystitis Upper Tract 
Pap genotypea, totalb 247 215 32  
Positive  106 (43) 88 (41) 18 (56) n.s. 
PapG alleles, total 247 215 32  
papGIA2  59 (24) 48 (22) 11 (34)  
prsGJ96  50 (20) 41 (19) 9 (28)  
papGIA2+prsGJ96  8 (3) 8 (4) 0 (0)  
P fimbrial expression, total  247 215 32  
Positivec 104 (42) 88 (41) 16 (50) n.s. 
P fimbrial subtypes, total 104 88 16  
Class IId  (PapG) 80 (77) 67 (76) 13 (81) n.s. 
Class IIIe (PrsG )  24 (23) 21 (24) 3 (19) n.s. 
a Analysis based on restriction fragment length polymorphism. 
b Total = number of isolates examined for each parameter. 
c Agglutinated human P1 but not p erythrocytes.   
d Class II P fimbriated strains defined by agglutination of human A1P1, OP1 but not p 
erythrocytes.  
e Class III P fimbriated strains defined by agglutination of human A1P1 but not OP1 or p 
erythrocytes. 
 
 
Table 2.  Pap genotype and P fimbrial expression in E. coli isolates 
 
 
4.2.3. The presence of a combined virulence profile 
 
The E. coli isolates were assigned a virulence profile based on their expression of 
virulence factors (Figure 8). The complete virulence factor repertoire (fim, papG/prsG, TcpC 
genotypes and curli) was present in 18% of the isolates. Strains expressing the complete 
virulence factor profile were significantly more common in patients with upper tract 
involvement compared to acute cystitis only (15% vs. 37%, p<0.01). 35% of all the strains had 
a combined virulence factor with the fim, papG/prsG sequences and curli, while 76% of the 
strains were fim+ and expressed curli. Both combinations were more common in patients with 
upper tract involvement (p =0.001 and p <0.05 respectively). There were no significant 
differences between strains from sporadic or recurrent UTIs. 
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Figure 8. Combined virulence repertoire of the strains. Strains with the combined virulence repertoire were 
more common in the subgroup of patients with acute cystitis and upper tract involvement compared to patients 
with acute cystitis alone. 
 
 
5. DISCUSSION 
 
Virulence factors are instrumental in bacterial infections, as they enhance the ability of 
the microorganisms to disseminate and overcome host defenses. Pathogens causing urinary 
tract infections, unlike most commensal bacteria may possess many different virulence factors, 
which influence the site and severity of urinary tract infections. The different virulence factors 
play role in different steps of the UTI pathogenesis, and their expression can be variable 
depending the environment and the host. Despite the extensive research the specific virulence 
factors responsible for the different clinical manifestations of UTIs have not been convincingly 
identified. 
In our investigation we aimed to analyze the role of the different bacterial virulence 
factors in the clinical course and outcome of urinary tract infections caused by Escherichia coli. 
With the analysis of E. coli 83972 strains isolated from symptomatic episodes during 
deliberately established asymptomatic E. coli 83972 bacteriuria we wanted to identify if there 
is a change in the virulence profile of these strains responsible for the transition from the stable 
asymptomatic state to symptomatic lower urinary tract infections. Next, we analysed clinical E. 
coli isolates from urinary tract infections to determine if Escherichia coli strains causing acute 
cystitis can be characterized by a distinct virulence factor repertoire, and if their virulence factor 
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profile can be distinguished from the strains causing acute pyelonephritis. 
 
 
5.1. Analysis of E. coli 83972 strains isolated from symptomatic episodes during 
deliberately established bacteriuria 
 
The method of deliberately established asymptomatic E. coli 83972 bacteriuria is an 
effective alternative method for preventing recurrent urinary tract infections. Furthermore it 
creates a unique opportunity to investigate how the bacteria and the host interact during 
asymptomatic colonization of the urinary tract. Many asymptomatic bacteriuria strains have 
lost the ability to express virulence factors due to point mutations and deletions and these strains 
do not trigger the mucosal inflammatory response that characterizes infection with fully virulent 
strains. In particular, although E. coli 83972 carries the different virulence genes, it does not 
express functional virulence factors. A personalized bacterial adaptation was observed during 
previous colonization studies, and this adaptive bacterial evolution pointed towards 
commensalism rather than virulence during asymptomatic bladder colonization [61]. Evolution 
toward virulence in colonizing E. coli 83972 strains have not been reported.  
Patients colonized with E. coli 83972 developed symptoms of urinary tract infections 
significantly less frequent compared to controls in the randomized controlled inoculation study 
by Sundén et al. Most of the symptomatic episodes were triggered by superinfections caused 
by other uropathogens, only five cases of symptomatic UTI episodes caused by the colonizing 
E. coli 83972 strains were documented. To detect if changes in bacterial virulence are 
responsible for the rare development of symptoms during asymptomatic carriage we 
investigated genotypic and phenotypic changes in the bacterial re-isolates that might have 
triggered the symptomatic episodes. 
We could not prove a reacquisition of virulence factors as a cause of symptoms in our 
analysis, however. The ExPEC virulence-associated gene set was identical in the E. coli 83972 
wild type and symptomatic re-isolates, suggesting that the overall pathogenicity island structure 
remained largely intact. Also, the expression of classical virulence factors, such as fimbrial 
adhesins, LPS and capsule as well as biofilm formation were not changed by the re-isolates, 
and we did not observe increased growth rates either.  
Since bacterial adhesion is a key-step in the pathogenesis of urinary tract infections, we 
performed further adhesion studies on uroepithelial cells to rule out the possibility that the re-
isolates acquired new adhesins that has not been analysed earlier. However, we did not find any 
difference between the adhesion capacity of the symptomatic re-isolates and the wild type. 
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Increased motility compared to the wild type was the only shared feature we found in 
two of the re-isolates. Flagella have been proposed to provide a selective advantage in the early 
colonization of the urinary tract [33] and flagellum-driven motility is proposed to enhance 
bacterial dissemination to the upper urinary tract and facilitate bacterial spread to sites more 
advantageous for colonization [76]. Sp10 was a 100% motile re-isolate, whereas R15-2 
contained a mixture of motile and non-motile cells. Transcriptomic analysis identified 
individually de-regulated genes in these two isolates mainly involved in stress responses, 
metabolism and LPS biosynthesis, but no common expression pattern was detected. Flagella 
biosynthesis and assembly was found to be upregulated only in one of the re-isolates, Sp10. 
However, we did not observe any difference during the in vitro host response induction 
experiment between the motile re-isolates and the wild type strain, or any motility-related 
differences in bacterial persistence during the in vivo murine infection model. 
As flagella were found to be involved not just in motility, but in bacterial adhesion as 
well in case of Enteropathogenic E. coli [77] and Salmonella spp. [78] [79] their possible role 
as adhesive organelles was also proposed in the urinary tract. However, in a study by Wright et 
al the authors did not find flagellation to be a significant factor in the adhesion and invasion of 
uroepithelial cells [75]. Our data support this finding, as flagella did not to promote adhesion 
in the case of the re-isolates. The results imply that although two of the re-isolates were motile, 
their motility did not contribute to an increased virulence in the urinary tract. 
To exclude the possibility that the symptomatic re-isolates acquired any unidentified 
virulence factors not measured by the previous investigations, we compared the virulence of 
the re-isolates with the E. coli 83972 wild type using an in vitro cell host response experiment 
and in vivo experimental murine UTI model. We did not observe any difference in the host 
response induction in A498 human kidney cells by the re-isolates compared to the wild type 
measured by IL6 and IL-8 secretion. Also, there were no significant differences in the bacterial 
virulence between the re-isolates compared to the wild type in the murine UTI model in respect 
of bacterial counts in urine, kidneys and bladders, kinetics of neutrophil recruitment, or 
mortality. If the development of symptoms were due to changes in bacterial virulence, we would 
have expected the re-isolates to trigger an increased host response in vitro and show an 
increased fitness in the in vivo UTI model. This would have been reflected by higher counts in 
bladders and kidneys and in parallel, we would have expected these strains to trigger an 
inflammatory response not observed after infection with the wild type strain. Such changes 
were not observed, however. Thus, our results suggest that the symptomatic episodes during 
long-term asymptomatic carriage of E. coli 83972 do not reflect regained expression of 
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established virulence factors. 
The individual changes in the pattern of phenotypic traits and the transcriptional profile 
of the re-isolates may suggest that these changes may be attributed to the involvement of 
response mechanisms of the hosts and not only on the characteristics of the bacteria. For 
example up-regulation in the genes coding for acid stress response in R15-2 clone I may 
indicates that this re-isolate has undergone a drastic change in environmental pH. 
Moreover, since there were no distinct general changes in the virulence among the re-
isolates which could explain the occurrence of symptoms, it may seem reasonable to speculate 
whether such symptomatic episode was not triggered by bacterial changes in virulence but 
changes within the host itself. Even if the patients have been stably colonized with E. coli 83972 
without triggering any sign of infection for many months, there may have been changes in the 
homeostasis of the patients during the course of time (i.e. older age, temporary decrease in the 
general immune status) which could have increase their susceptibility to environmental 
stressors which aided the immune system to recognize E. coli 83972, and could have led to a 
host driven break in the tolerance of asymptomatic colonization. 
The method of deliberately established asymptomatic E. coli 83972 bacteriuria is an 
effective non-antibiotic based alternative approach for preventing recurrent urinary tract 
infections. Although previous colonization studies concluded that deliberate establishment of 
asymptomatic bacteriuria is a safe procedure without side effects [59, 80], it is reasonable to be 
peculiarly careful when inoculating patients with bacteria. Our results provide strong evidence 
that even in the rare case of symptomatic episodes caused by E. coli 83972, colonizing bacteria 
did not reacquire virulence, and did not regain potential to cause serious infections to the 
patients, thus underlining the safety of the method. 
 
5.2. Virulence factor analysis of clinical Escherichia coli isolates from urinary tract 
infections 
 
 
Though the molecular background of acute cystitis has been extensively studied in the 
past, while pyelonephritis-associated molecular traits have been defined, virulence factors 
specific for acute cystitis strains have not been identified.  In the second part of our 
investigation, we examined if we can characterize clinical Escherichia coli isolates causing 
acute cystitis by a distinct set of virulence factors, and if their virulence profile can be 
distinguished from the strains causing acute pyelonephritis. 
We found type 1 fimbriae to be the most characteristic virulence factor for E. coli strains 
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causing acute cystitis, as 96% of the strains carried the fim gene cluster and 81% expressed 
functional type 1 fimbriae, supporting their role in bladder infection. Although curli were 
expressed by 73% of cystitis strains, only 15% of them formed biofilm. The expression of P 
fimbriae and TcpC were more characteristic to the strains causing upper UTIs. The presence of 
a complete or a combined virulence profile for the tested virulence factors (fim, papG, prsG, 
TcpC and curli) were not characteristic in the acute cystitis group. On the other hand, strains 
expressing the complete or combined virulence factor profile were significantly more common 
in patients with upper tract involvement. 
The presence of fim sequences and type 1 fimbrial expression were the most common 
features of the cystitis isolates in our analysis. Type 1 fimbriae are ubiquitously expressed by 
uropathogenic E. coli as well as other Gram-negative bacteria. Although type 1 fimbriae have 
been implicated in cystitis pathogenesis and shown to be essential virulence factors in the 
murine UTI model [81], as most E. coli isolates carry the fim operon regardless of their source 
[25], their role as independent virulence factors has been debated [67].  
The expression of type 1 fimbriae was shown to characterize the most virulent members 
of a single clone, as the disease severity of UTI was greater in children infected with E. coli 
O1:K1:H7 isolates expressing type 1 fimbriae than in those infected with type 1 negative 
isolates of the same serotype and a deletion of the fim gene cluster from that background was 
shown to attenuate virulence in the murine UTI model [26]. Type 1 fimbriae were also shown 
to promote bacterial attachment and trigger a partially TLR4 dependent innate immune response 
in the murine model [81]. Type 1 fimbriae are also required for UPEC-induced urothelial 
apoptosis [82, 83]. In vitro studies have shown that upon type 1 fimbrial binding to uroplakin 
complexes on the uroepithelial surface the disruption of superficial epithelium by type 1 pilus-
dependent apoptosis enables bacteria to invade the underlying immature cells [84], and form 
intracellular biofilm-like structures, called intracellular bacterial communities (IBCs) [24, 85].  
Type 1 fimbriae were also proposed to have an important function in the intracellular 
aggregation and maturation of IBCs [24]. IBCs act as intracellular bacterial reservoirs and have 
been proposed to play a key role in recurrent UTIs [86].  
Previous human inoculation studies provided somewhat contradictory results, however, 
as transformation of E coli 83972 with functional fim gene cluster followed by human 
inoculation did not trigger a higher innate immune response than the wild type strain and there 
was no difference in the establishment of bacteriuria [67]. In our analysis of E. coli 83972 re-
isolates from symptomatic episodes during deliberately established bacteriuria we did not find 
re-acquisition of type 1 fimbrial expression to be involved in the transition from asymptomatic 
39 
 
state to symptomatic episodes either. 
The high frequency of type 1 fimbrial expression in the present analysis of E. coli strains 
from patients with acute cystitis is consistent with a contribution of type 1 fimbriae to acute 
cystitis pathogenesis supporting their role in bladder infection either during the colonization 
phase or by enhancing inflammation and symptoms.  
Biofilm consists of microorganisms and their extracellular products forming a structured 
community on a surface. The low frequency of biofilm forming strains in the cystitis group 
compared to the isolates from upper urinary tract involvement in our data suggests that biofilm 
formation is more associated with the pathogenesis of acute pyelonephritis rather than acute 
cystitis. Similar results were obtained by other groups in adults [87] and children [88]. On the 
other hand, Mabbett et al found biofilm formation to be less pronounced in pyelonephritis 
compared to ABU or acute cystitis [89], while Soto et al observed no differences between 
cystitis and pyelonephritis strains regarding biofilm formation [90]. Biofilm formation was also 
found to be associated with recurrent pyelonephritis in children recently [88]. 
 The pap gene cluster is strongly associated with acute pyelonephritis and urosepsis but 
in acute cystitis strains reported frequencies have been below 50%, suggesting a less strong 
effect on bladder infections than in the kidneys [22, 91]. Our results correspond to these data, 
as P fimbrial expression was more dominant in the upper urinary tract infection than in acute 
cystitis strains.  
TcpC is a TIR domain homologous protein secreted by UPEC, which promotes bacterial 
survival by inhibiting the innate host response. Cirl et al described TcpC as a novel virulence 
factor in 2008 [48]. They found TcpC sequences to be present in about 40% of acute 
pyelonephritis isolates and 21% of cystitis isolates. TcpC was also shown to be more associated 
with acute pyelonephritis and urosepsis in a recent publication by Vejborg et al [91]. Our results 
confirmed the strong association of TcpC with disease severity. 
We could not characterize the strains causing acute cystitis with a distinct set of 
virulence factors. In view of the variability in virulence profile, we speculate that acute cystitis 
may be triggered by a convergent host response, allowing bacteria with different virulence 
profiles to cause the characteristic clinical symptoms. 
However, the presence of a complete or a combined virulence profile was significantly 
more common in the isolates causing upper urinary tract infections in women compared to the 
isolates form acute cystitis. The same tendency was shown in children [92] and men [93]. 
This theoretically means that with virulence factor profiling of the pathogens we can 
gain information about the clinical course of UTIs. In the traditional management of urinary 
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tract infections urologists focus mainly on the patients (host side) and try to make risk 
assessments of the possible disease severity based on patient characteristics, such as co-
morbidity, the presence of complicating factors, immunosuppression, etc. [94]. The 
investigation of the pathogens is superficially included the decision making, and is practically 
reduced to the results of urine cultures, and antibiotic susceptibility. However, with the 
characterization of the bacterial virulence factor profile it is possible to make risk assessments 
about disease severity with the investigation of the bacteria itself.  
According to the current guidelines asymptomatic bacteriuria only needs to be treated 
before an invasive genitourinary procedure and in case of pregnancy [95], because ABU can 
lead to the development of pyelonephritis and also has been associated with low birth weight 
and prematurity [96, 97]. In every other condition (diabetes, postmenopausal women, urinary 
foreign bodies, etc.) treatment of asymptomatic bacteriuria is not recommended, as the low risk 
of a severe urinary tract infection to evolve does not counterweight the cost meant by the vast 
amount of antibiotic usage. If we could predict the possibility of a severe infection in case of a 
clinical asymptomatic bacteriuria by identifying bacteria with a virulence potential, we could 
selectively treat patients who are in risk of a serious infection.  
In the era of increasing antibiotic resistance and multidrug-resistant bacteria deeper 
understanding of the causative bacteria and the analysis of bacterial virulence profile can be a 
valuable asset. Urologists need to widen their diagnostic arsenal from the traditional urological 
methods to a more microbiology-centered aspect in the future in order to be able to successfully 
manage the increasing threat of urinary tract infections. 
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6. CONCLUSIONS 
 
 
1. Our results suggest that symptomatic episodes caused by E. coli 83972 during deliberately 
established asymptomatic bacteriuria do not reflect regained expression of established 
virulence factors by the colonizing strain. 
 
2. The individual changes in the pattern of phenotypic traits and the transcriptional profile of 
the re-isolates suggest that these changes may be attributed to the involvement of response 
mechanisms of the hosts and not only on the characteristics of the bacteria. 
 
3. Our results verify that the deliberately established asymptomatic bacteriuria for preventing 
recurrent urinary tract infection is a safe method, as even in the rare case of symptomatic 
episodes caused by E. coli 83972 colonizing bacteria did not reacquire virulence, and did 
not regain potential to cause serious infections to the patients. 
 
4. Clinical strains causing acute cystitis could not be characterized with a distinct virulence 
factor repertoire. The most characteristic virulence factor was the expression of type 1 
fimbriae. 
 
5. The presence of a complete or a combined virulence profile was significantly more common 
in the isolates causing upper urinary tract infections. 
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7. ÖSSZEFOGLALÁS 
 
A húgyúti fertőzések klinikai jelentősége több szempontból is kiemelkedő, hiszen 
miközben a kórokozók antibiotikumokkal szembeni rezisztenciája világszerte növekedő 
tendenciát mutat, a húgyúti fertőzések képezik az antibiotikum felhasználás egyik vezető okát, 
továbbá a nozokomiális fertőzések egyik legfontosabb forrását szerte a világon. A téma 
fontossága ellenére a húgyúti fertőzések molekuláris alapjairól, illetve a kórokozók és a 
szervezet közötti interakcióról csak korlátozott ismeretek állnak rendelkezésünkre.  
A húgyúti kórokozók fertőzőképességét, illetve a kialakuló fertőzés súlyosságát 
nagymértékben befolyásolja, hogy az adott baktériumtözs milyen virulencia faktorokkal 
rendelkezik. Számos különböző virulencia faktort írtak le, melyek befolyásolják a húgyúti 
fertőzések patogenezisének különböző szakaszait, azonban nem tisztázott, hogy a különböző 
klinikai formák (tünetmentes bacteriuria, cystitis, pyelonephritis, stb.) kialakulásában a 
szervezeti tényezőkön túl pontosan mely virulencia faktorok és milyen módon játszanak 
szerepet.  
 Jelen kutatás célja a leggyakoribb húgyúti kórokozó, az Escherichia coli virulencia 
faktorainak tanulmányozása volt a húgyúti fertőzések klinikai lefolyásában. Vizsgálatunk első 
szakaszában azt a kérdést kívántuk megválaszolni, hogy az Escherichia coli 83972 törzsek 
virulenciájában bekövetkezett változás áll-e a mesterségesen kialakított tünetmentes E. coli 
83972 bacteriuria során kialakult, a kolonizáló törzs által okozott alsó húgyúti tünekkel járó 
epizódok hátterében.  
A mesterségesen kialakított tünetmentes bacteriuria módszerének lényege, hogy egyéb 
kezelésre nem reagáló, visszatérő húgyúti fertőzésben szenvedő betegek húgyhólyagját a 
tünetmentes bacteriuriát okozó, avirulens E. coli 83972 törzsekkel kolonizáljuk, így egyfajta 
kolonizációs rezisztenciát hozva létre. Sundén és munkatársai 2010-ben egy randomizált, 
kontrollált kolonizációs vizsgálatban igazolták a módszer klinikai hatékonyságát. A vizsgálat 
során az E. coli 83972 törzsekkel kolonizált betegeknél szignifikánsan ritkábban alakultak ki 
húgyúti fertőzéses epizódok a fiziológiás sóoldattal kolonizált kontrollokkal összehasonlítva. 
Ezen epizódok többségét más baktériumokkal való felülfertőződés okozta, mindössze 5 esetben 
(4 betegben) igazolódott a kolonizáló E. coli 83972 törzs a tünetek hátterében. Vizsgálataink 
során ezen izolátumok virulenciáját analizáltuk. 
A baktériumtörzseken először genotípus meghatározást végeztünk az extraintesztinális 
fertőzést okozó E. coli törzsekhez köthető legfontosabb virulencia génekre vonatkozóan. Nem 
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találtunk különbséget a vad típushoz képest a fim (1-es típusú fimbria), pap (P fimbria), foc 
(F1C fimbria), hlyA (α-hemolysin), cnf1 (citotoxikus nekrotizáló faktor), fyuA (yersiniabactin 
sziderofór receptor), iroN (salmochelin sziderofór receptor), iuc (aerobactin sziderofór), kpsMT 
K5 (K5 tok) és a malX (patogenitási sziget marker) szekvenciákkal kapcsolatban.   
A fenotípus meghatározás során nem találtunk különbséget a virulencia faktorok 
expressziójával kapcsolatban sem. Az izolátumok nem expresszáltak 1-es típusú, P, vagy F1C 
fimbriákat. Az esetleges egyéb adhezinek jelenlétét A498 vese és T24 húgyhólyag sejteken 
végzett adhéziós kísérlettel zártuk ki. Az izolátumok biofilm képző képessége, curli, illetve 
cellulóz, valamint O antigén expressziója szintén megegyezett a vad típussal.  
Két izolátum esetében találtunk fokozott motilitást a vad törzshöz képest. A két izolátum 
génexpressziós vizsgálata során leginkább a stressz választ, metabolizmust, illetve az LPS 
szintézist érintő egyedi változásokat észleltünk,  a flagella (ostor) szintézisének fokozódása 
csak az egyik izolátum esetén volt kimutatható.  
Az izolátumok virulenciájának további tesztelésére, és valamilyen esetlegesen jelen 
lévő ismerelten virulencia faktor kiszűrésére in vitro és in vivo virulencia kísérleteket 
végeztünk. Az izolátumok által A498 vesesejteken kiváltott in vitro immunválasz nem 
különbözött a vad törzs által kiváltott választól a sejtek interleukin 6 és 8 szekréciója 
tekintetében. Hasonlóképpen nem találtunk különbséget az izolátumokkal, illetve a vad típussal 
kolonizált C3H/HeN egereknél a vizeletben, húgyhólyagban és vesékben mért baktériumszám, 
a neutrophil granulocyták kinetikája, illetve a mortalitás tekintetében.  
Vizsgálatunk második szakaszában azt a kérdést kívántuk megválaszolni, hogy az akut 
cystitist okozó Escherichia coli törzsek karakterizálhatóak-e valamilyen jellegzetes virulencia 
faktor repertoárral, illetve, hogy ez megkülöböztethető-e az akut pyelonephritist okozó törzsek 
virulencia profiljától. Akut húgyúti fertőzésben szenvedő nők vizeletéből izolált 247 E. coli 
törzsnél végeztünk virulencia faktor analízist az akut cystitisben felmerült legfontosabb 
faktorok jelenlétére, illetve azok kombinációjára vonatkozóan, összehasonlítva az 
eredményeket a fertőzés klinikai lefolyásának függvényében, azaz, hogy felső húgyúti fertőzés 
kialakult-e, vagy sem.   
Az 1-es típusú fimbriák jelenléte volt a leggyakoribb az akut cystitist okozó törzseknél, 
a fimbriát kódoló fim szekvenciák az izolátumok 96%-ában voltak jelen, a fimbriákat az 
izolátumok 80%-a expresszálta. Ugyan curli-fimbriák 73%-ban voltak jelen a cystitis 
csoportban, biofilm képzést csak az izolátumok 15%-ánál észleltünk. Nem találtunk 
szignifikáns különbséget sem az 1-es típusú fimbriák, sem a biofilm képzés tekintetében az akut 
cystitist és az akut pyelonephritist okozó törzsek között. 
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A P fimbriákat kódoló pap génklaszter az összes törzs 43%-ban volt azonosítható (papG 
IA2 24%,  prsGJ96 20%, mindkettő 3%), akut cystitis esetén 41%-ban, felső húgyúti érintettség 
esetén 56%-ban. A P fimbriák expresszióját (Class II+III) az összes izolátum 43%-ában, a 
cystitist okozó törzsek 41%-ban, a felső húgyúti érintettséggel járó csoport esetén 50%-ban 
észleltük. A pap gének és a P fimbriák tekintetében észlelt különbség azonban nem volt 
szignifikáns a két csoport között. A TcpC expressziója szignifikánsan gyakoribb volt felső 
húgyúti érintettség esetén (42%) a csak cystitist okozó törzsekhez képest (32%) (p<0.01). A 
teljes, ill. halmozott virulencia profilt (fim, pap, TcpC és curli-fimbria) expresszáló törzsek 
szignifikánsan gyakoribbak voltak felső húgyúti érintettség, mint csak cystitis esetén (37% vs. 
17%, p<0.01). Nem találtunk szignifikáns különbséget a visszatérő ill. sporadikus húgyúti 
fertőzésekből izolált törzsek virulencia profiljában. 
Összefoglalva, a mesterségesen kialakított tünetmentes Escherichia coli 83972 
bacteriuria során kialakult, a kolonizáló törzs által okozott alsó húgyúti tünekkel járó epizódok 
hátterében a törzsek fokozódott virulenciája nem volt igazolható. Eredményeink arra utalnak, 
hogy a tünetek létrejöttében valószínűleg a gazdaszervezet állapotában kialakult változások 
játszhattak döntő szerepet, továbbá megerősítik a módszer klinikai alkalmazásának biztonságos 
voltát. 
A húgyúti fertőzésekből izolált Escherichia coli törzsek vizsgálata során az akut cystitist 
okozó E. coli törzsek az 1-es típusú fimbriák expressziójával voltak leginkább jellemezhetők. 
Az akut cystitist okozó törzsek jellegzetes virulencia faktor repertoárral nem voltak 
karakterizálhatóak, azonban felső húgyúti érintettség kialakulása esetén a kombinált virulencia 
faktor profil szignifikánsan gyakrabban volt jelen.  
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Rare Emergence of Symptoms during Long-Term
Asymptomatic Escherichia coli 83972 Carriage without
an Altered Virulence Factor Repertoire
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and Acronyms
ABU ¼ asymptomatic bacteriuria
cnf1 ¼ cytotoxic-necrotizing
factor1
fyuA ¼ yersiniabactin receptor
hlyA ¼ a-hemolysin
IFNg ¼ interferon-g
IL ¼ interleukin
iroN ¼ salmochelin receptor
iuc ¼ aerobactin
kpsMT K5 ¼ K5 capsule
LPS ¼ lipopolysaccharide
PMN ¼ polymorphonuclear
leukocyte
UTI ¼ urinary tract infection
wt ¼ wild typePurpose: Asymptomatic bacteriuria established by intravesical inoculation of
Escherichia coli 83972 is protective in patients with recurrent urinary tract in-
fections. In this randomized, controlled crossover study a total of 3 symptomatic
urinary tract infection episodes developed in 2 patients while they carried E. coli
83972. We examined whether virulence reacquisition by symptom isolates may
account for the switch from asymptomatic bacteriuria to symptomatic urinary
tract infection.
Materials and Methods: We used E. coli 83972 re-isolates from 2 patients in a
prospective study and from another 2 in whom symptoms developed after study
completion. We phylogenetically classified the re-isolates, and identified the
genomic restriction patterns and gene expression profiles as well as virulence
gene structure and phenotypes. In vivo virulence was examined in the murine
urinary tract infection model.
Results: The fim, pap, foc, hlyA, fyuA, iuc, iroN, kpsMT K5 and malX genotypes
of the symptomatic re-isolates remained unchanged. Bacterial gene expression
profiles of flagellated symptomatic re-isolates were unique to each host,
providing no evidence of common deregulation. Symptomatic isolates did not
differ in virulence from the wild-type strain, as defined in the murine urinary
tract infection model by persistence, symptoms or innate immune activation.
Conclusions: The switch from asymptomatic E. coli 83972 carriage to symp-
tomatic urinary tract infection was not explained by reversion to a functional
virulence gene repertoire.Accepted for publication July 22, 2013.
Study received approval from the Lund University human ethics committee and Lund District Court animal experimental ethics committee.
Supported by Swedish Medical Research Council Grant 2010-3070, Medical Faculty, Lund University, The Torsten S€oderberg and €Osterlund
Foundations, Maggie Stephens Foundation; Inga-Britt and Arne Lundberg Foundation, HJ Forssman Foundation for Medical Research and the
Royal Physiographic Society, Riksf€orbundet f€or Trafik och Polioskadade, Swedish National STRAMA (Swedish Strategic Programme against
Antibiotic Resistance), Region Skane FoU, the Foundations of G€osta J€onsson, Hillevi Fries, Per-Olof Str€om and Greta Ekholm, Lund, Sweden, ERA-
NET PathoGenoMics II (Federal Ministry of Education and Research Grant 0315436A), German Research Foundation Grant SFB1009 TPB05, a
fellowship from the International Graduate School of Life Sciences, University of W€urzburg (ES), Deutsche Forschungsgemeinschaft Grant DO
789/4-1 (UD) and the European Urological Scholarship Programme, European Association of Urology (BK).
* Equal study contribution.
† Financial interest and/or other relationship with OM Pharma.
‡ Correspondence: Institute of Hygiene, University of M€unster, Robert Koch-Str. 41, 48149 M€unster, Germany (telephone: þ49 (0)251
9802875; FAX: þ49 (0)251 9802868; e-mail: dobrindt@uni-muenster.de).
See Editorial on page 287.
0022-5347/14/1912-0519/0
THE JOURNAL OF UROLOGY®
© 2014 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
http://dx.doi.org/10.1016/j.juro.2013.07.060
Vol. 191, 519-528, February 2014
Printed in U.S.A.
www.jurology.com j 519
520 EMERGENCE OF SYMPTOMS DURING ASYMPTOMATIC ESCHERICHIA COLI 83972 CARRIAGEKey Words: urinary bladder, urinary tract infections, Escherichia coli, virulence, gene expressionBACTERIA invading the urinary tract may cause
symptomatic disease or give rise to ABU, a symptom-
free carrier state resembling commensalism.1 ABU
is even more common than symptomatic UTI.1,2
Epidemiological studies show that asymptomatic
carriage protects the patient against symptomatic
superinfections2,3 compared to patients in whom
bacteriuria is eradicated by antibiotic therapy.3
This protective effect has been used as a rationale
to deliberately establish ABU in patients prone to
UTI.46 The therapeutic efficacy of this approach
was demonstrated in randomized clinical trials.5,7
Observational studies established that therapeutic
inoculation is safe and decreases UTI morbidity.8,9
The prototype ABU Escherichia coli strain
839723,6 is extensively used for human inoculation
since it produces no adverse effects, fails to express
virulence factors associated with symptomatic UTI
and lacks conjugative plasmids.4 E. coli 83972 and
other ABU strains have a smaller genome size than
uropathogenic strains. This is due in part to viru-
lence gene deletions that abolish fimbrial expression
and adherence, suggesting that ABU strains adapt
to the human urinary tract by undergoing reductive
evolution.9
After therapeutic E. coli 83972 inoculation in
a series the number of symptomatic episodes
decreased during E. coli 83972 bacteriuria and pa-
tients experienced a longer infection-free interval
than a placebo group.6 While most symptomatic UTI
episodes were caused by superinfection with other
E. coli or nonE. coli strains, we identified a few
patients in whom symptoms developed during
E. coli 83972 bacteriuria, suggesting a transition
from ABU to symptomatic UTI.
In the current study we examined whether E. coli
83972 evolves toward virulence during asymptom-
atic carriage in the urinary tract. We compared
phenotypic and genotypic traits of E. coli 83972 to
those of re-isolates from patients with symptomatic
episodes. We found no evidence of increased
expression of traditional virulence factors by E. coli
83972 in hosts with symptomatic UTI during
asymptomatic carriage.METHODS
Patients and Study Design
Patients with incomplete bladder emptying due to spinal or
lower motor neuron lesions who had recurrent lower UTIs
were included in a placebo controlled study of intravesical
inoculation with E. coli 83972. In all patients optimal
treatment, including clean intermittent catheterization,had been tried but failed. Study exclusion criteria were
upper urinary tract dilatation, febrile UTI episodes or
pyelonephritis, corticosteroid treatment and significant
comorbidity. The study was approved by the Lund Uni-
versity human ethics committee and patients provided
informed consent (RTP-A2003, www.ClinicalTrials.gov).
Sunden et al previously reported patient characteristics
and identification numbers, diagnostic criteria and
study design.6
Before inoculation preexisting bacteriuria was elimi-
nated by antibiotic treatment. After an antibiotic-free
interval E. coli 83972 bacteriuria was established by
intravesical inoculation of 105 cfu/ml in saline. The pro-
cedure was repeated once daily for 3 days. After bacteri-
uria was established the effect on UTI morbidity was
quantified as the total number of symptomatic UTI epi-
sodes during 10 to 12 months compared to UTI morbidity
after a crossover period of similar duration without E. coli
83972 bacteriuria.
Symptomatic UTI Episodes
We examined the subset of patients in whom symptomatic
UTI episodes developed during the study (see table).
UTI episodes were self-reported, a method previously
shown to be reliable in select patient groups.10 UTI was
also determined in a structured interview by the study
physician and by urine culture yielding greater than
105 cfu/ml of a single organism. Symptomatic episodes
were defined by at least 2 symptoms, including supra-
pubic pain, dysuria and/or frequency as well as increased
spasticity in patients with a spinal cord lesion. Antibiotic
treatment initiated by the study physician resulted in
prompt relief of symptoms.
Bacteria and Cytokines
Urine samples were semiquantitatively cultured and the
antibiotic susceptibility pattern was recorded. Isolated
bacteria were maintained as deep agar stabs or frozen
glycerol cultures. For E. coli species verification of isolates
16S rRNA sequencing was performed with phenotypes
different from E. coli 83972. E. coli 83972 re-isolates were
identified by polymerase chain reaction, which detected
the cryptic 1.6 kb plasmid and the internal 4,253 bp fim
deletion. For in vitro analysis strains were grown in
lysogeny broth or in pooled human urine with or without
1.5% agar (Difco).
Neutrophils were quantified in uncentrifuged urine
using a hemocytometer chamber. IL-6 and 8 concentrations
were quantified by Immulite assay. The MILLIPLEX
MAP Human Cytokine/Chemokine Panel was used to
screen for additional cytokines.
DNA Techniques
QIAGEN products were used for genomic DNA iso-
lation. Primers were obtained from Eurofins MWG/
Operon, Ebersberg, Germany. Restriction enzymes were
obtained from New England Biolabs. Genomic DNA was
analyzed by pulsed field gel electrophoresis. Phylogenetic
Data on 4 patients with E. coli 83972 asymptomatic bacteriuria and total of 5 proven UTI episodes caused by E. coli
Pt R4
Pt R15 (episode No.)
Pt R10 Pt Sp101 2
Pt data
Gender F F F M
Yr born 1944 1958 1957 1937
Diagnosis Detrusor insufficiency,
post-void residual
urine
Detrusor insufficiency,
post-void residual
urine
Detrusor insufficiency,
post-void residual
urine
Spinal lesion, neurogenic
bladder disorder
UTI episode:
Days after E. coli 83972 inoculation 192 20 19 104 67
Symptoms Suprapubic pain,
dysuria, frequency
Local discomfort,
dysuria, frequency
Suprapubic pain,
dysuria, frequency
Local discomfort, dysuria,
increased spasticity
Urine inﬂammatory response
During preceding E. coli 83972 bacteriuria:
IL-6 (pg/ml) 39.6 145.2 235.4 Mean 2.1 (range 2e2) Mean 6.9 (range 2e24)
IL-8 (pg/ml) 4,706 3,268 551 Mean 20.2 (range 5e62) Mean 518 (range 37e407)
Neutrophils ( 104) 240 960 800 Mean 0.6 (range 0e2) Mean 25 (range 8e24)
At UTI episode:
IL-6 (pg/ml) 18 145 235 8 300
IL-8 (pg/ml) 4,706 3,268 551 43 7,500
Neutrophils ( 104) 240 960 800 Not determined 20,000
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were determined as previously described.11
Virulence Factor Expression
Functional type 1, P, F1C fimbriae, hemolysis and motility
as well as O antigen, aerobactin expression and biofilm
formation were detected.11,12 Adhesion to the human uri-
nary tract cell lines A498 and T24, and curli and cellulose
expression were determined as described previously.13
Experiments were performed in triplicate. We determined
growth rates at 600 nm optical density in triplicate exper-
iments using different batches of pooled human urine.
Gene Expression Profiling
RNA preparation and microarray analysis were per-
formed as previously reported.9 For statistical significance
the 1-sample t-test was applied with the Bonferroni
correction. A cutoff of 1.7 (ln2) was used at p 0.09.
Experimental Infection
Experiments were performed with the permission of the
animal experimental ethics committee, Lund District
Court, Sweden. Female C3H/HeN mice bred at the MIG
animal facility were infected at age 6 to 12 weeks by
intravesical inoculation with E. coli 83972 wt or re-isolates
from each symptomatic episode.14 Themice were sacrificed
at 6 or 24 hours, or 7 days, and the kidneys and bladders
were removed. Infection was quantified by viable counts on
kidney and bladder homogenates. Neutrophils were quan-
tified in uncentrifuged urine using a hemocytometer
chamber.For statistical analysis the groupswere compared
by the paired t-test or Mann-Whitney test.RESULTS
E. coli 83972 Bacteriuria Delayed UTI Recurrences
and Decreased Number of Symptomatic UTI
Episodes
Re-isolates of E. coli 83972 were obtained from
patients who participated in a placebo controlledcrossover study of the protective effect of E. coli
83972 bacteriuria after deliberate inoculation of this
strain into the urinary tract.6 Patients were pro-
tected from symptomatic UTI, as defined by the
number of episodes, before study entry and while in
the placebo arm of the study. The mean number
of symptomatic episodes per patient-year was 1.2
during ABU and 4 before the study (paired t-test
p ¼ 0.000019, fig. 1, A). In the E. coli 83972 bacte-
riuria arm with 202 months of observation a total
of 13 symptomatic UTI episodes developed in 9 pa-
tients (0.8 per patient-year). This was significantly
lower than in the placebo arm with 168 months
of observation time during which 4 of 20 patients
had a total of 35 UTI episodes (2.5 per patient-year,
p ¼ 0.009). Median time to the first symptomatic
episodewas also significantly less in the placebo group
than during ABU (11.3 vs 5.7 months, p <0.013).
The 13 UTI episodes recorded during E. coli
83972 bacteriuria were further characterized. Ten
episodes were superinfections. E. coli 83972 was
replaced by a different E. coli strain in 7 episodes,
and by Pseudomonas aeruginosa, Enterococcus
faecalis and Proteus mirabilis in 1 each. In patients
R4 and R15 only E. coli 83972 was recovered
during 1 and 2 symptomatic episodes, respectively,
suggesting that symptoms were caused by this
strain (see table and fig. 1, B). Before symptoms
developed these patients carried E. coli 83972
asymptomatically without discomfort. The 3 symp-
tomatic episodes were accompanied by increased
urine polymorphonuclear leukocyte numbers and
increasedurine cytokine levels (see table, fig. 2,Aand
supplementaryfig. 1, http://jurology.com/). In patient
R4 an increase in RANTES, IP-10, sIL-2Ra, MCP-1,
IL-1a, IL-1RA and IFNg was observed and in pa-
tient R15 IL-6, sIL-2Ra and IL-1a were increased.
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Prior to
inoculation
All episodes
E. coli 83972 bacteriuria
E. coli 83972
infections
Superinfections
p = 1.42 x 10
p = 0.00000034
n 80 13 10 3
Patient ID Days afterinoculation
IL-6
(ng/L)
IL-8
(ng/L) PMN x104/mL Culture Isolate
E. coli
83972
R4 192 39.6 4706 240 E.coli 83972 R4
R15 20 145.2 3268 960 E.coli 83972 R15-1
R15 19 235.4 551 800 E.coli 83972 R15-2
Other bacteria
R2 69 19.8 2627 nd E.coli
R15 116 206.8 1626 562 Enterococcus faecalis
R16 103 4.4 9 0 E. coli; Proteus mirabilis
R16 12 nd nd nd E.coli
Sp2 332 nd nd 28 Pseudomonas aeruginosa
Sp5 88 nd nd nd E.coli
Sp5 95 4.4 7156 nd E.coli
Sp8 119 4.4 62 1 E.coli
Sp12 272 nd nd nd E.coli
Sp13 193 nd nd nd E.coli
A B
Figure 1. Symptomatic UTI episodes during E. coli 83972 bacteriuria. A, mean  SEM frequency (n) of symptomatic UTI episodes
during year before inoculation and during year with E. coli 83972 bacteriuria in 20 patients (paired t-test). B, innate immune
response of patients to symptomatic E. coli 83972 episodes quantified as urine cytokine and PMN levels.
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cytokine response in humanuroepithelial cells (fig. 2,
B and supplementary fig. 1, http://jurology.com/). In
all patients the peak mucosal response was several
fold higher during the symptomatic episode
compared to the preceding ABU period. In patient
R10 the preceding ABU response was low or absent.
Properties of E. coli 83972 Re-Isolates from
Symptomatic Episodes
To examine whether a change in bacterial proper-
ties precipitated the symptomatic episodes we
examined the 3 E. coli 83972 re-isolates. We also
included E. coli 83972 re-isolates from symptomatic
episodes in 2 patients. Patient R10 participated in
the therapeutic study but symptoms developed after
study completion. Patient Sp10, who received E. coli
83972 inoculation in a separate open study protocol,
was excluded from analysis due to corticosteroid
treatment (see table).
To identify E. coli 83972 re-isolates we screened
20 randomly chosen colonies for the presence of the
cryptic 1.6 kb plasmid and the internal 4,253 bp fim
deletion (fig. 3, A). Like the wt strain, re-isolates
were phylogenetically classified into the B2 lineage
and shared an identical genomic restriction pattern
(supplementary fig. 2, http://jurology.com/).
E. coli 83972 carries the type 1 (fim), P (pap),
F1C ( foc) fimbrial genetic determinants and genes
coding for hlyA or cnf1, fyuA, iroN, iuc, kpsMT K5
and the pathogenicity island marker malX.11 These
genes were present in all re-isolates, suggestingthat the overall pathogenicity island structure
remained largely intact (fig. 3, B).
Re-isolates did not express functional P, F1C or
type 1 fimbriae (fig. 3, C ). To exclude other adhesins
we monitored adherence to A498 kidney cells and
T24 bladder cells but it was not detected (fig. 4, A).
We observed no consistent change in biofilm, curli or
cellulose formation (figs. 3, C and 4, B).
Re-isolates expressed an O antigen pattern
identical to that of E. coli 83972 (supplementary
fig. 2, http://jurology.com/). They had a growth rate
in pooled human urine similar to that of E. coli
83972 except re-isolates R10 and R15-1 clone II,
which grew more slowly (fig. 4, C ).
Re-Isolate Population Heterogeneous Phenotypes
Although urine samples from symptomatic episodes
were E. coli 83972 monocultures, re-isolates of
samples R15-1 and R15-2 showed heterogeneous
phenotypes and comprised colonies of different sizes
or motility. For colonies from urine sample R15-1
about 75% the colony size and morphology resem-
bled those of strain E. coli 83972 (R15-1 clone I). The
remaining colonies (R15-1 clone II) were small and
grew slowly (fig. 4, C ). However, they had the same
1.6 kb cryptic plasmid, fim deletion, restriction
pattern and virulence gene content as E. coli 83972.
The slow growth and reduced colony size were
reminiscent of small colony variants associated with
persistent infection.15 Furthermore, individual col-
onies of urine sample R15-2 differed in motility and
flagella expression.
Figure 2. Host response to ABU in vivo and in vitro. A, host response to symptomatic E. coli 83972 episodes. B, geometric mean  SEM
epithelial response to in vitro infection of A498 cells with E. coli 83972 wt, symptomatic E. coli 83972 re-isolates and uropathogenic
E. coli strain CFT073 in 2 independent experiments. Fetal calf serum (FCS) (5%) was used to provide soluble CD14.
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Since flagella were proposed to facilitate ascending
UTI,16,17 we compared the motility of E. coli 83972
and the re-isolates. Increased motility was observed
for re-isolates R15-2 and Sp10. R15-2 appeared
as a phenotypically heterogeneous population with
increased motility of individual cells (R15-2 clone I)
and flagellar expression relative to E. coli 83972
(fig. 4, D and supplementary fig. 3, http://jurology.
com/). The remaining re-isolates (R15-2 clone II)
were as motile as E. coli 83972.
Motile Re-Isolate Gene Expression Analysis
To analyze differences in the gene expression of re-
isolates with phenotypes that markedly deviated
from the wt we compared the transcriptome be-
tween E. coli 83972 and the motile re-isolates (R15-2
clone I and Sp10). Of 95 de-regulated genes in R15-2clone I 80 were up-regulated and 15 were down-
regulated while 81 and 17 of 98 genes in Sp10
were increased and decreased, respectively (fig. 5).
Most up-regulated genes in R15-2 clone I encoded
bacteriophage components. In addition, activated
genes were involved in the SOS or stress response
(recA, recN, lexA, ruvB, dinI, dinB, sulA, yebG,
osmB and umuD), s factor expression (rpoA, rpoE
and rpoS ) and acid resistance ( gadA, gadB, hdeAB,
cadB and slp). mglAB genes that code for a galac-
tose transporter and some phage related genes were
down-regulated. In E. coli R15-2, representing a
heterogeneous group of motile and less motile col-
onies, increased flagellar gene expression was less
pronounced.
In contrast, in re-isolate Sp10, in which all col-
onies showed increased motility, flagella biosyn-
thesis and assembly genes (flgA, flgDEFG, flhA,
Figure 3. Virulence gene repertoire and characteristics of E. coli 83972 and symptomatic re-isolates. A, 1.6 kb plasmid and fim deletion
were amplified by polymerase chain reaction (PCR) to verify E. coli 83972 identity in patient urine. B, identical virulence gene set was
identified in E. coli 83972 and symptomatic re-isolates. C, E. coli 83972 and re-isolate phenotypic characteristics.
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together with genes involved in heat shock
response ( groEL and groES ), LPS biosynthesis
(rfaGPIJY, waaV, waaW and lpxAB), amino sugar
use ( glmUS ) and iron uptake (chuATUWXY and
entCA). Transport genes were significantly down-
regulated, including aga, srl and dgo.
The yjbE and yqjD genes involved in biofilm
formation were commonly up-regulated in R15-2
clone I and Sp10 compared to E. coli 83972, as
were gudD and gudP involved in D-glucarate use,
and genes coding for 30S and 50S ribosomal subunit
components. Transcription of ribose transporter
genes was repressed in each re-isolate relative to
the wt.
Accordingly, transcriptional regulation was
unique for bacteria recovered from each host. Itprovided no evidence of commonly deregulated genes
in re-isolates from different symptomatic hosts.
Bacterial Persistence and Host Response
Activation In Vivo
To investigate whether the re-isolates showed
increased virulence we established in vivo infections
in C3H/HeN mice. There was no significant differ-
ence in the bacterial number in kidneys and blad-
ders 24 hours and 7 days after inoculation (fig. 6, A).
Urine neutrophil counts reflected the low acute in-
flammatory response to E. coli 83972. Motility of the
re-isolates did not influence bacterial numbers or
urine neutrophil counts (fig. 6, A).
E. coli 83972 was compared to the strain
83972DfliC mutant, which does not express func-
tional flagella. SN25, the most motile asymptomatic
Figure 4. Phenotypic characterization of E. coli 83972 re-isolates from symptomatic episodes. A, adhesion to T-24 bladder epithelial
cells and A498 kidney epithelial cells. B, biofilm formation in pooled human urine. C, growth kinetics in pooled human urine
in vitro. D, motility on urine swarm agar plates.
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We observed a biphasic infection pattern. Five
hours after infection E. coli 83972 and SN25
reached significant numbers while the kidneys of
mice colonized with E. coli 83972DfliC remained
sterile, consistent with a role for flagellation in the
early phase of ascending infection.16 At 7 days
persistent bacteriuria (greater than 105 cfu/ml)
developed in mice infected with E. coli 83972 and
83972DfliC. The highly motile isolate was elimi-
nated more rapidly than the wt and no increase
in the urine neutrophil number was related to
flagellation (fig. 6, B).DISCUSSION
After comparing the genome of E. coli 83972
re-isolates from different inoculated human hosts
we previously suggested that evolution toward
commensalism is favored during asymptomatic
bladder colonization.9 The current study was
designed to address whether evolution toward
virulence may occur in parallel in specific hosts. To
detect changes in bacterial properties associated
with the rare development of symptoms during
asymptomatic carriage we investigated phenotypicor genotypic changes in re-isolates that might have
precipitated the symptomatic episodes.
After 202patient-months ofE. coli 83972ABUonly
3 symptomatic UTI episodes with E. coli 83972 were
recorded. Analysis of these isolates and an additional
2 re-isolates from symptomatic episodes excluded
regained expression of virulence factors as a cause
of symptoms. LPS and capsule as well as biofilm
formation and adherence properties remained un-
changed. Deregulated genes were mainly involved
in different stress responses, metabolic versatility
and LPS biosynthesis but no common expression
pattern was detected. Flagellation was perturbed
but differences in virulence were not observed in the
murine UTI model. Results suggest that the occa-
sional symptomatic UTI episode does not reflect
regained expression of established virulence factor in
E. coli 83972 during long-term carriage.
Interestingly, we observed phenotypic variation
in the E. coli 83972 monoculture populating the
bladder. This behavior mirrored adverse and stress
conditions, and it may ensure the fitness and sur-
vival of a subset of cells in this niche. The presence
of 2 phenotypes in a clonal population18 suggests
bistable gene expression facilitating the exploitation
of dynamic host environments and promoting gene
Figure 5. Gene expression profiling of individual re-isolates. A, gene expression in re-isolates relative to E. coli 83972. Most regulated
genes were unique to each isolate. B, hierarchical cluster analysis of deregulated genes in re-isolates relative to E. coli 83972. Strains
were grown in vitro at 37C in pooled human urine. Values represent mean expression ratio of at least 3 independent microarray
experiments. Green areas indicate significantly regulated (log twofold change, p <0.05) suppressed genes. Red areas indicate
significantly regulated (log twofold change, p <0.050) up-regulated genes. Black areas indicate genes without statistically
significant change (p >0.05).
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infection.19 Examples of such heterogeneous phe-
notypes correlated with increased fitness of Vibrio
cholerae20 and E. coli.21 Flagellin expression of
Salmonella typhimurium also underlies bistable
gene regulation22 but host environmental factors
driving these changes remain poorly understood.
Small colony variant formation in Staphylococcus
aureus or P. aeruginosa23,24 has correlated with
chronic infection and in Campylobacter jejuni it is
considered a survival strategy relying on stress fit
individuals in a heterogeneous population.25 There-
fore, bacterial adaptation to long-term in vivo
growth in the urinary tract could include phenotype
switching. Alternatively, the occurrence of hetero-
geneous populations at symptomatic episodes may
represent spontaneous stochastic events, including
minor transient populations.
If symptom development were due to changes
in bacterial virulence, the re-isolates should have
shown increased fitness in the murine UTI model,
as reflected by a higher count in the bladders and
kidneys. In parallel, we would have expected these
strains to trigger an inflammatory response that was
not observed after infection with the wt strain.
However, such changes were not observed. The
highly flagellated asymptomatic strain SN25
attained a significant number in kidneys 5 hours
after infection. This suggests that flagellar motility
may be important for initial ascent of bacteria to
the upper urinary tract but this was cleared earlierthan the wt strain. In contrast, the 83972DfliC
mutant established persistent bacteriuria without
upper urinary tract involvement, similar to human
ABU.This implies that increasedflagellar expression
may be counterproductive for long-term persistence.
Symptomatic episodes were accompanied by an
innate immune response with increased cytokine
and chemokine levels in urine as well as pyuria.
IL-6 and 8 responses in symptomatic UTI have been
extensively studied and the concentrations reflect
disease severity.26 A recent experimental study
suggested a potential role for noninflammatory host
responses, showing distinct symptomatic responses
to bacteriuria mediated by TLR4 that are indepen-
dent of inflammation.27 However, in our study
all symptomatic UTI episodes were accompanied
by increased cytokine levels. Additional proin-
flammatory cytokines included IL-1a, which was
counterbalanced by the IL-1 receptor antagonist
IL-1RA, as well as RANTES, which was associated
with eosinophil/mast cell activation. The increase in
soluble IL-2Ra and IFNg confirmed a response
profile previously observed in patients with E. coli
83972 bacteriuria.28 These findings are consistent
with local lymphocyte and dendritic cell activation,
and infection dependent formation of lymphoid fol-
licles in patients with long-term ABU. The follicles
resolve after antibiotic eradication of bacteriuria,
confirming that they are driven by infection. How-
ever, there was no evidence of follicle formation in
patients who carried E. coli 83972.6
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Figure 6. Geometric mean  SEM values of re-isolate virulence, as defined by in vivo infection (Mann-Whitney test). A, experimental
infection of C3H/HeN mice by intravesical inoculation with 109 cfu in 0.1 ml E. coli 83972 or re-isolates from symptomatic episodes.
Bacterial number in urine, kidneys and bladders, and neutrophil response revealed no difference in virulence (Mann-Whitney test).
B, role of increased flagellation and motility were compared for E. coli 83972 wt and highly motile re-isolate Sp10. Mutant strains
E. coli 83972 DfliC::cat and SN25, highly motile re-isolate from asymptomatic carrier, served as negative and positive control,
respectively. Bacterial numbers in urine, kidneys and bladders, and neutrophil influx revealed no long-term advantage for
flagellated strains.
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In the absence of functional virulence factors and
shared molecular changes in bacteria the mecha-
nism behind the emergence of symptoms remains
unclear. A possibility is a host driven break in
the tolerance of asymptomatic colonization, which
triggers spurious pathogen recognition signaling.
However, it is intriguing to speculate that the
molecular events that precipitate cystitis symptoms
have a different mechanistic nature than that of
acute pyelonephritis. It is also intriguing that the
few study patients in whom symptoms developed
during ABU strain carriage may share what is to our
knowledge an as yet undefined host response pattern
that leads to immune overactivity and symptoms.ACKNOWLEDGMENTS
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Bacterial virulence factors inﬂuence the site and severity of urinary tract infections. While
pyelonephritis-associated molecular traits have been deﬁned, virulence factors speciﬁc for acute cystitis
strains have not been identiﬁed. This study examined the virulence factor repertoire of 247 Escherichia
coli strains, prospectively isolated from women with community-acquired acute cystitis. Fim sequences
were present in 96% of the isolates, which also expressed Type 1 ﬁmbriae. Curli were detected in 75%, 13%
of which formed cellulose. Pap sequences were present in 47%, 27% were papGþ, 23% were prsGþ and
42% expressed P ﬁmbriae. TcpC was expressed by 33% of the strains, 32% in a subgroup of patients who
only had symptoms of cystitis and 42% in patients with signs of upper urinary tract involvement; most
frequently by the papGþ/prsGþ subgroup. Strains with the full ﬁm, pap and TcpC and curli virulence
proﬁle were more common in cystitis patients with than in patients without upper tract involvement
(p< 0.05). The varied virulence proﬁle of E. coli strains causing acute cystitis suggests that diverse
bacterial strains, expressing Type 1 ﬁmbriae trigger a convergent host response, involving pathways that
give rise to the characteristic symptoms of acute cystitis.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
The severity of urinary tract infections (UTI) reﬂects the viru-
lence and tissue speciﬁcity of the infecting strain. Acute pyelo-
nephritis is caused by a restricted subset of uropathogenic
Escherichia coli (UPEC) clones, distinguished for example by O:K:H
serotypes or E. coli reference collection types combined with
speciﬁc virulence factors with speciﬁc functions during the
pathogenesis of infection [1]. Adhesins, including P and Type 1
ﬁmbriae facilitate tissue attack and toxins perturb diverse cellular
functions [1,2]. TcpC, a homolog of the Toll/Interleukin-1 receptor
domain is a new type of virulence factor, which acts by inhibiting
Toll-like receptor (TLR) signaling [3]. These virulence factors
increase the ﬁtness of UPEC for the renal environment and aid
them to resist elimination by the host defense. Through their
interactions with host cells, the virulence factors trigger the
innate immune response, leading to symptoms like fever, general
malaise and ﬂank pain.atharina.svanborg@med.lu.se
All rights reserved.Acute cystitis is a more common but less well-deﬁned disease
entity than acute pyelonephritis, characterized by inﬂammation of
the lower urinary tract with symptoms like dysuria, frequency and
suprapubic pain. Acute cystitis strains form an intermediary group
with respect to O:K:H serotype diversity, ECOR types and certain
virulence gene frequencies [1,2,4,5]. Type 1 ﬁmbrial expression
alone has been discussed as major virulence factors in acute cystitis
as these ﬁmbriae enhance virulence in the murine urinary tract
[6,7e9], through attachment to the bladder mucosa. Receptor
epitopes are provided bymannosylated host cell glycoconjugates in
sIgA [10], uroplakins on bladder cells, CD48 on mucosal mast cells
[11], integrins b1 and a3 [12] and Tamm-Horsfall Protein (THP) [13]
and diverse signaling pathways trigger bacterial internalization and
innate immunity. On the other hand, human inoculation studies
have so far not conﬁrmed the role of Type 1 ﬁmbriae for persistence
and inﬂammation in the urinary tract [9,14,15]. Toxins such as
hemolysin (hly) and cytotoxic necrotizing factor (CNF) enhance
uroepithelial damage [16] and curli and cellulose support bioﬁlm
formation but there is no evidence that these properties are unique
for acute cystitis strains or more abundant in this group [17]. Acute
cystitis strains also express P ﬁmbriae [4,5,18e20] and three PapG
adhesin variants have been identiﬁed [21]. The reported frequen-
cies of P ﬁmbriated strains vary among acute cystitis isolates as
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and thus, the contribution of the PapG adhesin variants to
bladder infection remain unclear.
In this study, we have usedmolecular epidemiology to address if
strains causing acute cystitis have a distinct virulence factor
repertoire. The results show that Type 1 ﬁmbriae and curli are
common in acute cystitis isolates but analysis of multiple virulence
factors did not deﬁne a cystitis-speciﬁc virulence proﬁle. These
ﬁndings raise the question if the symptoms of acute cystitis actually
result from the action of speciﬁc virulence factors, especially Type 1
ﬁmbriae which are most abundant among these strains, or if the
pathogenesis of acute cystitis is fundamentally different from that
of acute pyelonephritis, in terms of the variety of organisms that
can give rise to a similar symptom proﬁle. Understanding the
pathogenesis of acute cystitis thus remains a major challenge.
2. Materials and methods
2.1. Patients
Women 18 years of age were enrolled in a controlled
randomized treatment trial of symptomatic UTI in general practice
[23]. They had signiﬁcant bacteriuria (>104 cfu/mL) and were
assigned a diagnosis of acute cystitis based on frequency, dysuria
and/or suprapubic pain, a temperature <38.0 C and no ﬂank pain.
Patients who also had ﬂank pain and/or fever (>38.0 C) were
diagnosed as having acute cystitis with upper urinary tract
involvement. On admission, a history of previous UTI, concomitant
disease and medical treatment were recorded. The UTI episode was
classiﬁed as sporadic (<two episodes during the previous six
months or<three during the previous 12 months) or recurrent and
as uncomplicated or complicated if the patient had structural or
functional abnormalities of the urinary tract.
2.2. Host response to infection
Blood samples were obtained at diagnosis and examined for C-
reactive protein (CRP, cut off 10 mg/L), white blood cell counts
(cut off 10109/L) and erythrocyte sedimentation rate (ESR, cut
off> 25 mm/h).
2.3. Urine cultures
Midstream urine samples were obtained at diagnosis. Quanti-
tative urine cultures identiﬁed 247 E. coli growing as monocultures,
and the isolates were stored in deep agar stabs. For analysis,
bacteria were grown overnight on tryptic soy agar plates at 37 C.
The urinary tract is normally sterile, and urinary tract infections are
usually caused by a single bacterial strain, originating from the fecal
ﬂora [24,25]. Infections by multiple organisms are associated with
long-term catheterization or mechanical disorders affecting the
urine ﬂow [26].
2.4. Pap, ﬁm, papG and TcpC genotypes
P ﬁmbriae are encoded by the pap operon [27]. The pap geno-
type was determined by DNAeDNA hybridization with probes
speciﬁc for the 50 (HindIII) and 30 (SmaI) fragments of the pap
operon and derived from the pap gene cluster [22]. The papG
adhesin isotypes were deﬁned by PCR, using primer pairs that
matched unique regions of the papGIA2, prsGJ96 sequences [28].
Whole bacterial cells provided template DNA and primers did not
cross-amplify other papG sequences, as shown by the recombinant
strains containing a single known copy of papGIA2 or prsGJ96. The P
ﬁmbriated E. coli IA2 and E. coli J96, and the pap positiverecombinants E. coli HB101 (papGIA2) and E. coli HB101 (prsGJ96)
were used as positive controls and E. coli HB101, E. coli AAEC
(pPKL4) as negative controls. The TcpC genotype was deﬁned by
PCR, using speciﬁc primer pairs deﬁning unique regions of the TcpC
sequences [3].
The ﬁmH genotype was deﬁned by PCR, using primer pairs that
matched unique regions of the adhesin sequences [28].
2.5. Bacterial phenotypes
Type 1 ﬁmbrial expressionwas detected by hemagglutination of
guinea pig and human erythrocytes after in vitro passage in Luria
broth. Agglutination was performed both in the presence and
absence of a-methyl-D-mannoside. Strains causing mannose-
sensitive agglutination were deﬁned as Type 1 ﬁmbriated [15].
The P-ﬁmbrial phenotype was deﬁned by P blood group-
dependent hemagglutination [22]. P-ﬁmbrial expression was
deﬁned by agglutination of P1 (receptor positive) but not p
(receptor negative) erythrocytes. Class II strains agglutinated A1P1,
OP1 but not A1p erythrocytes and Class III agglutinated only A1P1
and not OP1 erythrocytes. Strains, which agglutinated A1p eryth-
rocytes were assigned to a group with “other mannose resistant
adhesins”.
Morphotype analysis on Congo red and Calcoﬂour plates was
used to study curli and cellulose expression [17]. After overnight
culture, morphotypes were determined at daylight (Congo red) and
UV-light (Calcoﬂour), as previously described. Reference strains
were included and all strains were classiﬁed as curliþ and
celluloseþ, curliþ and cellulose, curli and cellulose and curli
and celluloseþ.
Bioﬁlm formation was quantiﬁed by the crystal violet method
[17]. Bacteria diluted in Luria-Bertani broth without salt were
seeded into 96-well plates, incubated overnight at 37 C without
shaking, washed, air-dried and stained with crystal violet (3%). The
dyewas solubilized with ethanol (95%) and the optical density (OD)
was measured at 570 nm. Ability to form bioﬁlms was deﬁned at an
OD 0.5.
2.6. Hemolysin production
Hemolytic strains were identiﬁed in nutrient agar with 5%
washed horse erythrocytes after overnight incubation. A hemolytic
zone larger than the overlying colony was considered positive [4].
2.7. Statistical analysis
Chi-square test or the Fisher’s exact test was used. p< 0.05 was
considered statistically signiﬁcant (two-tailed).
3. Results
3.1. Characteristics of the patient population at inclusion
Women with cystitis symptoms and bacteriuria (n¼ 247, mean
age 51 years, range 18e91) were included and their infecting E. coli
strains were saved. All but ﬁve patients had bacteriuria deﬁned as
105 cfu/mL (98%); the remaining had 104 cfu/mL of urine. Most
patients (83%) were healthy, except for the ongoing UTI episode,
but 39 had hypertension and/or diabetes (Table 1). The UTI episode
was sporadic in 73% while 16% had a history of childhood UTI,
indicating UTI susceptibility. Most of the patients (n¼ 215) had only
acute cystitis symptoms but a smaller group (n¼ 32, 13%) also had
ﬂank pain and/or fever, suggesting upper tract involvement
(Table A.1). This group had increased circulating CRP levels and
Table 3
Fim genotype, type 1 ﬁmbrial, curli/cellulose expression and bioﬁlm formation.
Virulence typing,
E. coli isolates
Total
No. (%)
Symptoms p Values
Cystitis
No. (%)
Upper tract
No. (%)
Fim genotypea 247 215 32
Positive 237 (96) 207 (96) 30 (94) n.s.
Type 1 expressionb,c 226 198 29
Positive 181 (80) 161 (81) 20 (71) n.s.
Hemolysin expressiond 245 213 32
Positive 68 (28) 60 (28) 8 (25) n.s.
Morphotypese 227 198 29
Curliþ and celluloseþ 30 (13) 27 (14) 3 (10)
Curliþ and cellulose 140 (62) 117 (59) 23 (79) p¼ 0.036
Curli and cellulose 57 (25) 54 (27) 3 (10)
Curli and celluloseþ 0 0 0
Bioﬁlm formationf 225 196 29
0.0e0.49 189 (83) 167 (85) 22 (76)
0.5 2 36 (16) 29 (15) 7 (24) n.s.
a Analyzed by PCR.
b Analyzed by hemagglutination.
c Information from 21 patients was missing.
d 16 strains had weak hemolysin production.
e Information from 20 patients was missing.
f Information from 22 patients was missing.
Table 1
Host background variables in women with acute cystitis.
Host background variables Patients No. (%)
Age, years median [range] 51.0 [18e91]
Medical events
No illnessa 205 (83)
Hypertensionb 31 (13)
Diabetes 8 (3)
Diureticsc 29 (12)
UTI history
Childhood UTI 39 (16)
Current UTI
Cystitis 215 (87)
Upper tract involvementd 32 (13)
Type of symptomatic UTIe,f
Sporadic uncomplicated 154 (62)
Sporadic complicated 26 (11)
Recurrent uncomplicated 56 (23)
Recurrent complicated 11 (4)
Total No. of patients 247
a Patients without any known illness other than UTI.
b One patient had both hypertension and diabetes, 26 patients with
hypertension received diuretics and 3 additional patients received diuretic
treatment without a diagnosis of hypertension.
c Diuretic treatments: tiazides (n¼ 14), loop-diuretics (n¼ 6), K-sparing
drugs (n¼ 1), combinations of diuretics (n¼ 8).
d Patients with ﬂank pain alone or in combination with cystitis symp-
toms and/or fever.
e Complicated UTI structural or functional abnormalities of the urinary
tract including diabetes.
f Sporadic UTI< 2 UTI episodes during the last 6 months or <3 during
the last 12 months.
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cystitis symptoms (p¼ 0.01 and p¼ 0.01 respectively, Table 2).
3.2. Fim genotype, Type 1 ﬁmbrial and hemolysin expression
As Type 1 ﬁmbriae have been implicated in cystitis pathogenesis
and shown to be essential virulence factors in the murine UTI
model, we ﬁrst deﬁned the Type 1 ﬁmbrial genotype by PCR using
ﬁm speciﬁc primers. The expression of Type 1 ﬁmbriae was also
detected by mannose-sensitive hemagglutination. Except ten
isolates, all were ﬁmþ (96%) and Type 1 ﬁmbrial expression was
detected in 80% of the isolates (Table 3). There was no signiﬁcant
difference in ﬁm frequency between isolates from patients with
acute cystitis (81%) and the subgroup which also had upper tract
involvement (71%) (Fig. 1A). Hemolysin expression was only
detected in 28% in the total sample and the frequency did not differ
between the two groups (Table 3). The results conﬁrm the high ﬁmTable 2
Laboratory parameters in women with acute cystitis.
Laboratory parameter Total No. (%) Symptoms p Values
Cystitis
No. (%)
Upper tract
No. (%)
C-reactive protein 247
>10 mg/L 67 52 (24) 15 (47) p¼ 0.01
White blood cell counts 242
>10 109/L 43 32 (15) 11 (35) p¼ 0.01
Erythrocyte
sedimentation rate
145
>25 mm/hg 50 45 (21) 5 (16) n.s.frequency among cystitis strains, consistent with these adhesins
being essential for the pathogenesis of acute cystitis.
3.3. Curli, cellulose and bioﬁlm expression
Curli are bacterial surface organelles that bind several host
extracellular matrix and contact phase proteins. These adhesive
ﬁbers enhance bacterial bioﬁlm formation on various abiotic
surfaces. To analyze curli expression as a virulence factor in acute
cystitis isolates, curli expression was examined by morphotype
analysis. Curli were detected in seventy-ﬁve per cent of the isolates;
73% in patients with acute cystitis compared to 89% of patients, who
also had upper tract involvement. Only 13% of the strains formed
cellulose (Table 3). The curliþ and cellulose phenotype was more
frequent in patients with upper tract symptoms (p< 0.05) (Fig. 1B).
Bioﬁlm, which consists of microorganisms and their extracellular
products forming a structured community on a surface, was
detected by the crystal violet method in <20% of all strains after
growth at 37 C, which was selected to resemble the conditions in
the urinary tract. The results suggest that strains causing acute
cystitis frequently express curli but bioﬁlm formation was mostly
not detected.
3.4. Pap/PapG genotypes and P-ﬁmbrial expression
The pap gene cluster is strongly associated with acute pyelone-
phritis and urosepsis but in acute cystitis strains reported
frequencies have been below 50%, suggesting a less strong effect on
bladder infections than in the kidneys. The P-ﬁmbrial G adhesin
determines the receptor speciﬁcity is localized at the tip of the
ﬁmbrial organelle and at least 3 isotypes have been distinguished,
based on receptor speciﬁcity of the G adhesin (Class I PapG, Class II
PapG and Class III PapG or PrsG). Two P-ﬁmbrial isotypes
predominate among uropathogenic E. coli. Class II G adhesins,
encoded by the papGIA2 sequences, recognize all P blood group
determinants. Class III G adhesins, encoded by the prsGJ96
sequences, recognize P blood group determinants with a terminal
blood group A residue [22,27]. Class I P ﬁmbriae (papGJ96) are
uncommon in clinical isolates.
Fig. 1. Virulence factor repertoire of Escherichia coli isolates fromwomen with acute cystitis. (A) Fim genotype and Type 1 ﬁmbrial expression in isolates from 247 patients, all with
symptoms of acute cystitis (n¼ 215) and a subgroup, who also had upper tract symptoms (n¼ 32). (B) Curli and cellulose expression of Fim genotype positive strains in the different
patient groups. The curliþ and cellulose phenotype was more frequent in the subset of patients with upper tract symptoms (p< 0.05). (C) and (D) Pap genotype and P-ﬁmbrial
expression in the different patient groups. (E) TIR homologous TcpC sequences in the different patient groups, and in relation to the pap genotype. (F) 23 isolates were weakly
positive and are not included. Signiﬁcantly higher TcpC frequency in patients with papGþ and/or prsGþ strains (p< 0.001 and p< 0.05). (F) Fim genotypes, curli/cellulose expression
and papG genotypes (G) in patients with no host compromise, patients with history of UTI and patients with medical events. The frequency of ﬁmþ and curliþ isolates was
increased in patients with medical events compared to those with a history of UTI (p< 0.05).
B.S. Norinder et al. / Microbial Pathogenesis 52 (2012) 10e16 13To further clarify this question, the P-ﬁmbrial gene cluster was
detected by DNA hybridization and adhesin isotypes (papG/prsG)
were identiﬁed by PCR, using speciﬁc primers. The pap gene cluster
was present in 43% of all isolates (Table 4). The papGIA2 adhesin
sequences were present in 24% and prsGJ96 sequences in 20% of all
isolates, while 3% of the isolates carried both adhesin genes (Fig. 1C
and D).
The P-ﬁmbrial phenotype is deﬁned by hemagglutination, using
erythrocytes speciﬁcally expressing the P blood group antigens in
the presence or absence of the A blood group determinant and withP blood group deﬁcient cells as a negative control. P-ﬁmbrial
expression (Class IIþ III) was detected by hemagglutination in 104
(42%) of the isolates (Table 4). Among those, Class II ﬁmbriae
(papGIA2) weremore common (77%) than Class III ﬁmbriae (prsGJ96)
(23%, p< 0.001). P blood group independent adhesins were found
in 13% of the strains.
P-ﬁmbrial expression was further examined as a function of the
papG genotype. As expected, most strains expressing Class II P
ﬁmbriae were papGþ (80%) and isolates expressing Class III P
ﬁmbriae were prsGþ (96%), 30% of the strains agglutinating A1p
Table 4
Pap genotype and P-ﬁmbrial expression in E. coli isolates.
Pap genotype and
P-ﬁmbrial expression
No. of isolates (%) p Values
All isolates Cystitis Upper Tract
Pap genotype,a totalb 247 215 32
Positive 106 (43) 88 (41) 18 (56) n.s.
PapG alleles,c total 247 215 32
papGIA2 59 (24) 48 (22) 11 (34)
prsGJ96 50 (20) 41 (19) 9 (28)
papGIA2þ prsGJ96 8 (3) 8 (4) 0 (0)
P-ﬁmbrial expression,d total 247 215 32
Positivee 104 (42) 88 (41) 16 (50) n.s.
P-ﬁmbrial subtypes, total 104 88 16
Class IIf (PapG) 80 (77) 67 (76) 13 (81) n.s.
Class IIIg (PrsG) 24 (23) 21 (24) 3 (19) n.s.
a Analysis based on restriction fragment length polymorphism.
b Total¼ number of isolates examined for each parameter.
c Analyzed by PCR.
d Analyzed by P blood group speciﬁc hemagglutination.
e Agglutinated human P1 but not p erythrocytes.
f Class II P ﬁmbriated strains deﬁned by agglutination of human A1P1, OP1 but not
p erythrocytes. There is a higher frequency of Class II P ﬁmbriae compared to Class III
in all three groups p< .001.
g Class III P ﬁmbriated strains deﬁned by agglutination of human A1P1 but not OP1
or p erythrocytes.
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might be masked in this group.
In patients with upper tract involvement, 56% of isolates were
papþ and 50% expressed P ﬁmbriae compared to 41% and 41% of the
isolates from patients without upper tract symptoms (p¼ 0.102 and
p¼ 0.332 respectively). There was no difference in Class II distri-
bution among patients with acute cystitis with or without upper
tract involvement, however (76% versus 81%, p¼ 0.75).
The results suggest that about half of acute cystitis strains are
papþ, that the papG genotype predominates over prsG and that
most papþ acute cystitis strains express functional P ﬁmbriae.3.5. TcpC genotype
TcpC is a TIR domain homologous protein secreted by UPEC,
which promotes bacterial survival by inhibiting the innate host
response and speciﬁcally MyD88 dependent signaling pathways
[3]. The TcpC genotype of the cystitis isolates was deﬁned by PCR,
using speciﬁc primers. TcpC was detected in 33% of the isolates, inFig. 2. Combined virulence repertoire including the ﬁm, tcpC, papG/prsG sequences and
respectively. Strains with the combined virulence repertoire were more common in the sub
with acute cystitis alone (p< 0.05).32% of patients with acute cystitis compared to 42% in the subset of
patients with upper tract symptoms (Fig. 1E). TcpC was more
common in the papGþ/prsGþ subset of the strains than in isolates
lacking papG and/or prsG (p< 0.01 and p¼ 0.01, respectively)
(Fig. 1F). The results conﬁrmed that papþ uropathogenic strains
express TcpC more often than pap strains, but showed no signif-
icant association with acute cystitis.
3.6. Virulence, UTI history and host compromise
Medical conditions that compromise the host defense have
previously been shownto inﬂuence the requirements forvirulence in
strains causing acute pyelonephritis [29]. The virulence factor proﬁle
was therefore compared between isolates from patients with dia-
betes/hypertension and those who were healthy except for the
ongoing UTI episode. Furthermore, genetic predisposition has been
shown to inﬂuence acute pyelonephritis susceptibility and the
frequency of UTI in this group. Isolates from patients with sporadic
infections were therefore compared to isolates from patients, who
had a history of UTI (Fig. 1G and H). There was no signiﬁcant differ-
ence in overall virulence proﬁle related to these host variables. The
frequency of ﬁmþ and curliþ isolates was increased in patients with
medical events compared to those with a history of UTI (p< 0.05).
3.7. Combined virulence proﬁle
The E. coli isolates were assigned a virulence proﬁle based on
their expression of virulence factors (Fig. 2). The complete virulence
proﬁle, comprising the ﬁm, papG/prsG and TcpC genotypes as well
as curli was detected in 18% of the isolates; 15% of the cystitis only
and 37% of the group with upper tract involvement (p< 0.01). 35%
of the strains carried the ﬁm, papG/prsG sequences and expressed
curli and this combination was also more common in patients with
upper tract involvement (p¼ 0.001). There was also a signiﬁcant
difference in the frequency of ﬁmþ strains with curli expression
between the two groups (p< 0.05). The results showed that strains
with the combined virulence proﬁle were signiﬁcantly more
common in patients with acute cystitis who had upper tract
involvement than in patients with only lower tract symptoms.
4. Discussion
The molecular basis of acute cystitis has been extensively
studied in cellular and experimental infection models [14,15,30].
Still, it remains unclear if a speciﬁc repertoire of virulence factorscurli formation in all patients, those with acute cystitis and upper tract symptoms,
group of patients with acute cystitis and upper tract involvement compared to patients
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of UTI. The present study examined E. coli isolates from 247 women
with acute cystitis, using a combination of virulence genes
commonly associated with acute pyelonephritis or cystitis. Type 1
ﬁmbrial expression and ﬁm sequences were common in the cystitis
isolates, supporting their role in bladder infection. Curli, which
have been proposed to improve bioﬁlm formation, adhesion to host
cells and internalization [31] were expressed by>70% of all isolates.
In contrast, P ﬁmbriae and TcpC were expressed by less than half of
the cystitis strains, with papG being somewhat more common than
prsG. A subgroup of strains expressed all the tested virulence factors
(ﬁm, papG, prsG, TcpC and curli) but such strains were not abundant
in the acute cystitis group. Consistent with a role of these virulence
factors in kidney infection, however, strains with the full virulence
genotype were most common in patients with acute cystitis and
upper tract involvement. The results suggest that Type 1 ﬁmbrial
expression is a unifying feature among acute cystitis strains, but
provide no evidence that the virulence gene repertoire distin-
guishes strains causing acute cystitis from other uropathogens. In
view of the variable virulence proﬁle and high frequency of Type 1
ﬁmbrial expression, we speculate that characteristic acute cystitis
symptoms may be triggered Type 1 ﬁmbrial interactions with the
bladder mucosa. The symptoms reﬂect a different repertoire of host
mediators than acute pyelonephritis possibly including bacterial
tethering of neuronal circuits in the mucosal compartment.
Type 1 ﬁmbriae are ubiquitously expressed by uropathogenic
E. coli as well as other Gram-negative bacteria. Due to this high
frequency, their role as independent virulence factors has been
debated [15]. Recently, strains causing asymptomatic bacteriuria
have been shown to carry ﬁm deletions, suggesting that an intact
ﬁm gene cluster may be counterproductive and that a loss of
functional type 1 ﬁmbriae promotes bacterial adaptation to long-
term bacterial carriage in the urinary tract. The high ﬁm
frequency in the present study is consistent with a contribution of
Type 1 ﬁmbriae to acute cystitis pathogenesis, either during the
colonization phase or by enhancing inﬂammation and symptoms
[9,14,15,30,32]. Furthermore, type 1 ﬁmbriae are major virulence
factors in the murine cystitis model, where they act by promoting
bacterial attachment and by triggering a partially TLR4 dependent
innate immune response [33]. FimH has also been shown to
suppress NFkB-dependent transcription of pro-inﬂammatory genes
[34,35] and Type 1 ﬁmbriae have been proposed to enhance E. coli
uptake into specialized dome cells in the bladder mucosa and
promote intracellular bacterial proliferation, thus creating persis-
tent infection and resistance to antibiotic therapy [36,37]. Binding
of the FimH adhesin to uroplakin complexes on the uroepithelial
surface mediates bacterial entry into uroepithelial cells [32,38]
through elevated cAMP levels [34]. In addition, Type 1 ﬁmbriae
may be involved in eliciting apoptosis in uroepithelial cells [35]. In
mucosal mast cells, FimH binding to the CD48 receptor has been
proposed to direct bacterial uptake.
Human inoculation studies have provided somewhat contra-
dictory results, regarding Type 1 ﬁmbriae and their contribution to
UTI. The prototype ABU strain E. coli 83972 fails to express Type 1
ﬁmbriae and gives rise to a weak host response. After trans-
formation of this strain with the ﬁm gene cluster followed by
human inoculation, the Type 1 ﬁmbriated strain did not trigger
a higher innate immune response than the wild type strain and
there was no difference in the establishment of bacteriuria, sug-
gesting that Type 1 ﬁmbriae might function differently in the
human and murine urinary tracts [15]. In addition to ﬁm sequence
variation, virulence for the urinary tract is modiﬁed by controlled
variation in Type 1 ﬁmbrial expression [30,39,40]. In a clinical study
of E. coli O1K1H7 and acute pyelonephritis in children, disease
severity was augmented when the infecting strain expressed bothType 1 and P ﬁmbriae compared to infections caused by the same
strain, but having lost Type 1 ﬁmbrial expression [40]. This differ-
ence was also observed in vivo, where reconstitution with func-
tional ﬁm sequences restored virulence in the murine model [30]
consistent with Type 1 ﬁmbriae contributing to kidney infection. In
the present study, Type 1 ﬁmbrial expressionwasmaintained in the
largemajority of the strains, suggesting that acute cystitis strains do
not loose Type 1 ﬁmbrial expression through phase variation or
mutation during the acute phase of infection, consistent with
a functional role for these ﬁmbriae in acute cystitis.
The efﬁciency of the bacterial virulence factors in causing UTI
depends on the immune status of the host. Innate immunity
controls many aspects of the host response to acute UTI and
variation on the efﬁciency of this response has been shown to
affect the degree of tissue damage and the clearance of infection
[41]. As a consequence, host genetic variants that modify the
innate immune response have been associated with different
forms of UTI [42,43]. In patients with recurrent UTI, which mostly
denotes cystitis, several genetic screens have proposed gene
associations, including promoter polymorphisms in LTA and TNFa
[44], in the coding regions of TLR1, TLR4 and TLR5 [45]. The
functional importance of these genetic variants in cystitis is not
well understood, however. Several genetic markers of acute
pyelonephritis have been established but have shown no associ-
ation with acute cystitis. Low expression of the chemokine
receptor CXCR1 is associated with APN susceptibility and CXCR1
gene polymorphisms are common in pyelonephritis prone indi-
viduals [46]. Other genetic markers of pyelonephritis suscepti-
bility include IRF 3 polymorphisms [43]. These genetic studies
emphasize the difference in pathogenesis and genetic control as
well as the symptoms typical of acute pyelonephritis and cystitis.
Finally, in ABU, genes like TLR4 may be mutated and promoter
polymorphisms have been associated with reduced TLR4
expression and ABU but not with acute cystitis [42]. In future
studies, it may be relevant to match bacterial properties against
the host immune repertoire, to better understand the patho-
genesis of acute cystitis.
It is interesting to speculate that acute cystitis strains may share
as yet undeﬁned virulence factors that speciﬁcally enhance the
attack on the bladder mucosa. The cystitis strains are genetically
diverse, however, and it appears less likely that strains of very
different clonal origin would share a new, disease-deﬁning cystitis-
speciﬁc virulence factor. The clinical presentation of disease might
instead be determined by the host response pathways, which are
activated by the different acute cystitis strains. Innate immunity is
crucial for the antimicrobial defense of the urinary tract, and TLR4
dependent signaling pathways have been shown to inﬂuence the
susceptibility to acute pyelonephritis and asymptomatic bacteri-
uria. It remains possible that distinct innate response circuits may
distinguish cystitis prone patients from patients prone to other
forms of UTI. In this case, strains with different virulence proﬁles
may converge on similar host signaling pathways creating the
characteristic acute cystitis symptoms. The relevant pathways and
host response dynamics need to be further explored.
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Appendix
See Table A.1.Table A.1
Signs and symptoms of acute cystitis at the time of diagnosis.
Symptoms Patients No. (%)
Lower tract symptoms only
Frequency and dysuria 92 (37)
Frequency, dysuria and suprapubic pain 71 (29)
Frequency or dysuria or suprapubic pain 39 (16)
Frequency, suprapubic pain or dysuria, suprapubic pain 13 (5)
Additional upper tract symptoms
Flank pain and/or fever 32 (13.4)
Total No. of patients 247References
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